

1 **Mannoside and 1,2-mannobioside  $\beta$ -cyclodextrin-scaffolded NO-photodonor for targeting**  
2 **antibiotic resistant bacteria**

3 Giovanna Cutrone,<sup>a</sup> Gábor Benkovics,<sup>b</sup> Milo Malanga,<sup>b</sup> Juan Manuel Casas-Solvas,<sup>a</sup> Éva Fenyvesi,<sup>b</sup>  
4 Salvatore Sortino,<sup>c</sup> Luis García-Fuentes,<sup>a</sup> Antonio Vargas-Berenguel<sup>a,\*</sup>

5 <sup>a</sup> Department of Chemistry and Physics, University of Almería, Carretera de Sacramento s/n, E-  
6 04120, Almería, Spain

7 <sup>b</sup> Cyclolab Kft, Illatos út 7, H-1097, Budapest, Hungary

8 <sup>c</sup> Department of Drug Sciences, University of Catania, Viale Andrea Doria 6, I-95125, Catania,  
9 Italy

10 \* Corresponding author. E-mail address: avargas@ual.es (A. Vargas-Berenguel).

11

12 **ABSTRACT**

13 Two  $\beta$ -cyclodextrin derivatives randomly appended on the primary face with both the nitric oxide  
14 (NO) photodonor 4-nitro-3-(trifluoromethyl)aniline and a mannose or  $\alpha(1\rightarrow2)$ mannobioside residue  
15 are reported to construct targeted NO photoreleasing nanocarriers. 2D ROESY and PGSE NMR  
16 suggested supramolecular homodimerization in water by inclusion of the nitroaniline group into the  
17 facing macrocycle cavities. Isothermal titration calorimetry on their concanavalin A lectin binding  
18 showed an exothermic binding event to the lectin and an endothermic process during the dilution of  
19 the conjugates. Both  $\alpha(1\rightarrow2)$ mannobioside and the nitroaniline moieties significantly enhanced the  
20 binding to the lectin. These effects might arise from a better fit within the carbohydrate-recognition  
21 site in the former case and a multivalent effect caused by homodimerization in the latter. Direct  
22 detection of NO by amperometric technique shows that both  $\beta$ -cyclodextrin derivatives release this  
23 radical upon excitation with visible light with higher efficiency than the unfunctionalized NO  
24 photodonor.

25 **KEYWORDS**

26  $\beta$ -Cyclodextrin;  $\alpha(1\rightarrow2)$ Mannobioside; Homodimerization; Concanavalin A; Nitric Oxide

27 **1. Introduction**

28 The emergence of pathogenic bacteria that show resistance to diverse antimicrobial active  
29 ingredients is a growing global health threat (Magiorakos et al., 2012). Commonly used  
30 antimicrobial therapies, such as the administration of antibiotic drugs, fail in providing an efficient  
31 treatment due to the ability of bacteria to develop resistance mechanisms to the action of such drugs  
32 (Woodford, 2005). Thus, biomedicine faces the demanding challenge of developing new treatment  
33 strategies against antibiotic Multi Drug Resistance (MDR) (Cohen, 2000; Laxminarayan et al.,  
34 2013; Taubes, 2008). In this regard, a very promising approach is based on the use of nitric oxide  
35 (NO) as a very efficient non-conventional antimicrobial and antioxidant. As well, this inorganic free  
36 radical has a key therapeutic role in a number of cancer and cardiovascular diseases (Carpenter &  
37 Schoenfisch, 2012; Halpenny & Mascharak, 2010). The NO radical presents a mechanism of action  
38 that avoids MDR problems, as it is considered a multitarget cytotoxic agent that is able to attack a

39 wide range of biological targets (Szakács, Paterson, Ludwig, Booth-Gent, & Gottesman, 2006).  
40 However, delivering gaseous NO to selected targets is a difficult challenge that has fostered the  
41 development of a range of molecular NO donors (Wang et al., 2002; Wang, Cai, & Taniguchi,  
42 2005; Riccio & Schoenfisch, 2012; Seabra & Durán, 2010). An interesting approach involves the  
43 use of biocompatible scaffolds as suitable vehicles able to release NO under light stimuli, namely  
44 NO photodors (NOPDs). These compounds offer the great advantage to deliver NO with high  
45 spatiotemporal control, thus favoring reducing side-effects and improving therapeutic outputs  
46 (Fraix, Marino, & Sortino, 2016).

47 Cyclodextrins are cyclomaltooligosaccharides well known for their applications in many  
48 different fields, but particularly in the supramolecular and pharmaceutical fields. Such molecules  
49 are able to enhance the water solubility, stability, bioavailability and organoleptic properties of a  
50 large number of drugs. The doughnut-shaped structures formed by six ( $\alpha$ -CD), seven ( $\beta$ -CD) and  
51 eight ( $\gamma$ -CD) linked glucoses, define an inner cavity of a relatively hydrophobic nature, inside of  
52 which a wide range of organic molecules of similar polarity and suitable size and shape can be  
53 hosted in aqueous media. Numerous studies carried out in humans and animals have shown that  
54 CDs can be very useful to improve drug delivery of therapeutic substances (Cutrone, Casas-Solvas,  
55 & Vargas-Berenguel, 2017; Duchêne, & Bochot, 2016; Popielec & Loftsson, 2017). The drug  
56 delivery strategy can be extended to NO therapy by the construction of photoactivatable CD-NOPD  
57 conjugates, either in covalent or non-covalent fashion, as delivery systems for the NO radical  
58 (Mazzaglia et al., 2012). Among others, 4-nitro-3-(trifluoromethyl)aniline derivatives are efficient  
59 NOPDs and suitable for bio-applications as they show dark stability and adequate absorption  
60 coefficient in the visible region, and produce NO radicals without generating toxic or light-  
61 absorbing byproducts, or altering environmental pH, temperature or ionic strength (Caruso, Petralia,  
62 Conoci, Giuffrida, & Sortino, 2007; Conoci, Petralia, & Sortino, 2006; Di Bari et al., 2016). The  
63 chromophore can enter within the cavity of  $\beta$ -CD, where the scarce contact with water molecules  
64 dramatically modifies both the light absorption efficiency and the mechanism of photochemical  
65 deactivation (Sortino et al., 2001). Indeed, within the hydrophobic microenvironment of a micelle,  
66 this NOPD has shown a remarkable enhancement of NO release efficiency (Di Bari et al., 2016).

67 The vast majority of viruses, bacteria and cells present on their surfaces a family of proteins  
68 called lectins that are able to specifically bind carbohydrates. This fact has allowed the development  
69 of drug delivery strategies based on the use of carbohydrates as selective biological vectors  
70 (Vargas-Berenguel, Ortega-Caballero, & Casas-Solvas, 2007; Casas-Solvas & Vargas-Berenguel,  
71 2016). Thus, by conjugating a molecular carrier to carefully selected carbohydrates it is possible to  
72 transport therapeutics to those cells presenting on their surfaces the complementary saccharide  
73 receptor. In particular, oligosaccharidic mannosyl structures, such as mannoside ( $\alpha$ -D-Man-  
74 (1 $\rightarrow$ 2)-D-Man) and mannotriptide ( $\alpha$ -D-Man-(1 $\rightarrow$ 2)- $\alpha$ -D-Man-(1 $\rightarrow$ 2)-D-Man), are intimately  
75 related with the pathogenicity of a good number of viruses and bacteria (Schuster, Vijayakrishnan,  
76 & Davis, 2015). For example, mannose-binding lectins (MBLs) such as FimH are displayed on the  
77 surface of many bacteria. Furthermore, cells of the immune system present a series of MBLs on  
78 their surfaces, such as macrophage-mannose receptors (MMR) on the macrophages and Dendritic  
79 Cell-Specific Intercellular adhesion molecule-3 (ICAM-3)-Grabbing Non-integrin (DC-SIGN) on  
80 the dendritic cells (Figdor, van Kooyk, & Adema, 2002). Thus, mannoside-CD conjugates able to  
81 produce antibacterial effects or to encapsulate antibacterial drugs could be used as target-specific  
82 antimicrobial delivery systems as a way to fight antibiotic resistance. However, this strategy is  
83 hindered by the intrinsic weakness of the saccharide-protein interaction, which can be overcome

84 through a multivalent presentation of the carbohydrate moieties to achieve a global binding potency  
85 toward the lectin higher than that for the sum of the monovalent entities (Bausanne et al., 2000;  
86 Benito et al., 2004; Vargas-Berenguel, Ortega-Caballero, & Casas-Solvas, 2007; Casas-Solvas &  
87 Vargas-Berenguel, 2016).

88 In this context, we describe herein the construction of photoresponsive  $\beta$ -CD derivatives  
89 having the CD scaffold covalently linked to the NOPD 3-(trifluoromethyl)-4-nitrobenzenamine and  
90 mannose or  $\alpha(1\rightarrow2)$ mannobioside as targeting functionalities, these latter having specific avidity  
91 for pathogens showing mannose-receptor lectins on their surface. We hypothesized that such  
92 structures would undergo a supramolecular self-aggregation process in aqueous solution through the  
93 inclusion of the NOPD within the  $\beta$ -CD. Such arrangement would result in a multivalent display of  
94 the carbohydrate moieties, as well as enhancing the NO-release efficiency due to the NO donor  
95 confinement inside the CD cavity. The formation of self-inclusion complexes was investigated by  
96 2D ROESY and pulse-gradient stimulated echo (PGSE) NMR experiments, while amperometric  
97 detection allowed us to estimate the light-stimulated release of the NO radical. Isothermal titration  
98 calorimetry (ITC) served to measure the binding efficiency of these new conjugates towards  
99 Concanvalin A (ConA) lectin as a mannose-specific model protein.

100

## 101 **2. Experimental part**

### 102 *2.1. Materials and methods*

103 Merck silica gel 60 F254 aluminum sheets were used for Thin Layer Chromatography  
104 (TLC). Plates were developed by UV-Vis light and stained with 5% v/v sulfuric acid in ethanol.  
105 Merck silica gel (230-400 mesh, ASTM) was used as stationary phase for flash column  
106 chromatography. Merck Celite 545 (0.002-0.1 mm) was used for filtration when stated. Uncorrected  
107 melting points measurements were taken with a Büchi B-450 melting point equipment. Optical  
108 rotations ( $[\alpha]_D$  values, (given in  $10^{-1}$  deg  $\text{cm}^{-1}$   $\text{g}^{-1}$ ) were measured on a Jasco P-1030 polarimeter at  
109 room temperature. Attenuated Total Reflectance (ATR) infrared spectra were measured on a Bruker  
110 Alpha FTIR equipment. MALDI-TOF mass spectra using 2,5-dihydroxybenzoic acid (DHB) as  
111 matrix were recorded on a 4800 Plus AB SCIEX spectrometer, while an Agilent LC/MSD-TOF  
112 spectrometer was used to measure ESI-TOF mass spectra. Dialysis was performed using Biotech  
113 CE Tubing MWCO: 100-500 D. Absorbance UV-Vis spectra were obtained using a Jasco V 650  
114 spectrophotometer.

115 D-(+)-Mannose ( $\geq 99\%$ , Acros), acetic anhydride (purum, Panreac),  $\text{BF}_3 \cdot \text{Et}_2\text{O}$  ( $\geq 46.5\%$   $\text{BF}_3$   
116 basis, Aldrich), sodium (purum, Panreac), benzoyl chloride (99%, Aldrich), trichloroacetonitrile  
117 (98%, Aldrich), potassium carbonate (purum, Panreac), benzoyl cyanide (98%, Aldrich), trimethyl  
118 orthoacetate (99%, Aldrich), D/L-10-camphorsulfonic acid (98%, Acros), benzoic anhydride ( $\geq 95\%$ ,  
119 Aldrich), 4-dimethylaminopyridine (99%, Fluka), trimethylsilyl triflate ( $\geq 98\%$ , Fluka), and  
120 copper(I) iodide (98%, Aldrich) were purchased from commercial sources and used without further  
121 purification otherwise indicated.  $\beta$ -CD (CycloLab) was dried at 50 °C in vacuum in the presence of  
122  $\text{P}_2\text{O}_5$  until constant weight was achieved. 7% HCl solution in MeOH was prepared by diluting 37%  
123 aqueous HCl solution (Panreac) in distilled MeOH. Triethylenamine ( $\geq 99\%$ , Sigma-Aldrich),  
124 pyridine (purum, Panreac), propargyl alcohol (99%, Acros), 2-aminoethanol ( $\geq 98\%$ , Sigma-  
125 Aldrich), and organic solvents were dried according to literature procedures (Perrin & Armarego,

126 1989). Dry DMF (99.8%, over molecular sieves, AcroSeal) was purchased from Acros. 4Å  
127 molecular sieves (VWR Chemicals) were heated at 200 °C under high vacuum for 12 hours for  
128 activation. 6<sup>L</sup>-Deoxy-6<sup>L</sup>-azido-6<sup>X</sup>-deoxy-6<sup>X</sup>-*N*-{3-[*N'*-(4'-nitro-3'-trifluoromethylphen-1'-  
129 yl)amino]propylamino}cyclomaltoheptaose **1** was synthesized as a mixture of regioisomers as  
130 previously reported by Benkovics et al. (2017) (see supplementary data for details). 6<sup>L</sup>-Azido-6<sup>L</sup>-  
131 deoxy-β-cyclodextrin **2** was purchased from CycloLab. Propargyl α-D-mannose **3** was prepared as  
132 described in literature (Poláková, Beláňová, Mikušová, Lattová, & Perreault, 2011; Zhao, Liu, Park,  
133 Boggs, & Basu, 2012) with small modifications. Specifically, purifications of both compounds after  
134 deacetylation were carried out by column chromatography using EtOAc-MeOH 6:1 as eluent. NMR  
135 data for these compounds in D<sub>2</sub>O completely agreed those described by Erdmann & Wennermers  
136 (2010) and van der Peet et al. (2006), respectively. *O*-(2,3,4,6-tetra-*O*-benzoyl-α-D-  
137 mannopyranosyl) trichloroacetamide **8** was prepared as described by Hartmann et al (2012).

## 138 2.2. NMR measurements

139 <sup>1</sup>H, <sup>13</sup>C and 2D NMR spectra were recorded on a Bruker Avance III HD 600 MHz  
140 spectrometer equipped with a QCI <sup>1</sup>H/<sup>13</sup>C/<sup>15</sup>N/<sup>31</sup>P proton-optimized quadrupole inverse cryoprobe  
141 with <sup>1</sup>H and <sup>13</sup>C cryochannels, a Bruker Avance III HD 500 MHz spectrometer equipped with an  
142 inverse TBI <sup>1</sup>H/<sup>31</sup>P/BB probe, or a Bruker Nanobay Avance III HD 300 MHz spectrometer using a  
143 QNP <sup>1</sup>H/<sup>13</sup>C/<sup>19</sup>F/<sup>31</sup>P probe, depending on the sample. Chemical shifts (δ) are given in parts per  
144 million (ppm) and *J* values are expressed in hertz (Hz). Residual solvent signals (δ<sub>H</sub> 7.26 and δ<sub>C</sub>  
145 77.16 ppm for CDCl<sub>3</sub>; δ<sub>H</sub> 4.79 ppm for D<sub>2</sub>O) were used as internal references. Water signal was  
146 suppressed in two-dimensional phase-sensitive gROESY experiments using WATERGATE 3-9-19  
147 pulse sequence with gradients. Stimulated echo diffusion measurements (Pregosin, Kumar, &  
148 Fernandez, 2005) were performed on 10 mM samples in 500 μL of D<sub>2</sub>O on the Bruker Avance 500  
149 without spinning using rectangular gradient pulses of variable strength, which was increased from  
150 10 to 98% in 8% steps) For each increment 128 scans were measured using a recovery time 5 times  
151 longer than the longest spin-lattice relaxation time (*T*<sub>1</sub>) measured for each sample prior to the  
152 experiment. The slope of the linear regression on Stejskal-Tanner plots were used to determine the  
153 *D* values according to

$$154 \ln\left(\frac{I}{I_0}\right) = -(\gamma\delta)^2 \left(\Delta - \frac{\delta}{3}\right) DG^2$$

155 where *I* and *I*<sub>0</sub> correspond to the signal intensity after and before applying gradients, respectively; δ  
156 is length of the gradient pulse (set to 4 ms), Δ is the delay between the midpoints of the gradients; *D*  
157 is the diffusion coefficient; and *G* is the gradient strength. Three gradient delays (Δ = 70-120 ms)  
158 were used to check the robustness of the results. Attenuation of the D<sub>2</sub>O signal was used for  
159 calibration of the gradients, giving a slope of 1.425 x 10<sup>-3</sup> when using δ = 1.75 ms and Δ = 167.75  
160 ms). At least 7 data points were used for least-square linear fits with correlation coefficients >0.999.  
161 Obtained *D* values were estimated to have an experimental error of ±2%.

162 Once obtained *D* values, Stokes-Einstein equation  $D = (k_B T)/(c\pi\eta r_H)$  was used to calculate  
163 the hydrodynamic radii (*r*<sub>H</sub>), assuming a spherical shape for β-CD, **ManβCD** and **BiManβCD**. In  
164 this equation *D* is the diffusion coefficient, *k*<sub>B</sub> is the Boltzman constant, *T* is the temperature, and η  
165 is the viscosity of the solvent (0.890 x 10<sup>-3</sup> kg m<sup>-1</sup> s<sup>-1</sup> for H<sub>2</sub>O as taken from www.knovel.com).  
166 Microfrictional factor *c* should be semi-empirically estimated according to ( $c = 6/[1 +$   
167  $\{0.695(r_{\text{soliv}}/r_H)^{2.234}\}]$ ), which take into account the ratio between the solvent and solute radii. In our

168 case,  $c$  can be approximated to 6 due to the fact that  $r_H \geq 5r_{\text{solv}}$ , as suggested by Macchioni,  
169 Ciancaleoni, Zuccaccia, & Zuccaccia, 2008. In contrast, **ManNOPD $\beta$ CD** and **BiManNOPD $\beta$ CD**  
170 were considered as prolate spheroids in order to take into account the potential dimerization process  
171 in water for these compounds. Their volumes were set as equal to those calculated for their  
172 equivalent spheres defined from the Stokes-Einstein equation. Their major semi-axes were then  
173 estimated assuming that their minor semi-axes could not be larger than  $r_H$  values calculated for their  
174 analogues **Man $\beta$ CD** and **BiMan $\beta$ CD**, respectively.

### 175 2.3. NO release measurements

176 NO release measurements are based on short response time (< 5 s) direct amperometric  
177 detection of the radical using a World Precision Instrument, ISO-NO meter, in the sensitivity range  
178 of 1 nM-20  $\mu$ M. A four-channel data acquisition system connected to a PC workstation was used to  
179 digitalize the analog signal. In order to calibrate the sensor, standard solutions of NaNO<sub>2</sub> were  
180 mixed with 0.1 M H<sub>2</sub>SO<sub>4</sub> and 0.1 M KI to generate known amounts of NO according to the  
181 reaction:



183 For NO release experiments, samples were placed in a thermostated quartz cell (1 cm path  
184 length, 3 mL capacity) and irradiated at  $\lambda$  405 nm under gentle stirring careful was taken to avoid  
185 the laser illumination of the electrode within the cell, which may result in false NO signals due to  
186 photoelectric artifacts.

### 187 2.4. Isothermal Titration Calorimetry (ITC) measurements

188 *Canavalia ensiformis* (Jack bean) concanavalin A (ConA) lectin (type VI, lyophilised  
189 powder) was purchased from Sigma and used as received. All solutions were prepared in MilliQ  
190 pure water (18.2 M $\Omega$ cm) and degassed for 10 min and thermostated prior each experiment. UV-Vis  
191 spectroscopy was used to calculate the lectin solution concentration ( $A^{1\%}_{280 \text{ nm}} = 13.7$  for the  
192 tetrameric form). ITC experiments were performed on an ultrasensitive VP-ITC (Microcal Inc.,  
193 Northampton, MA) as as previously described elsewhere (Casas-Solvas, Ortiz-Salmerón, García-  
194 Fuentes, & Vargas-Berenguel, 2008) and the calculus were performed using Origin software  
195 (provided by the instrument). Briefly, the calorimeter was calibrated as recommended by the  
196 manufacturer. The reference and sample cells were filled with degassed MilliQ water and the  
197 protein solution, respectively. The sample cell was continuously stirred at 320 rpm. Solutions of the  
198 mannosylated  $\beta$ CDs and ConA (see table S1 at supporting information for concentrations) were  
199 prepared in 20 mM phosphate buffer (pH 7.2) containing 20 mM NaCl, 100  $\mu$ M CaCl<sub>2</sub> and 100  $\mu$ M  
200 MnCl<sub>2</sub>. Each mannosylated  $\beta$ CD was injected in 8-10  $\mu$ L portions every 5 min with a 250  $\mu$ L  
201 syringe. The mannosylated  $\beta$ CDs were also injected into pure buffer in separate experiments in  
202 order to obtain the corresponding dilution background profiles, which turned out to be similar to the  
203 residual heat signals detected after saturation in the interaction experiments with the protein.  
204 Obtained thermograms depicted the transfer of heat per second following each injection of  
205 mannosylated  $\beta$ CD into the ConA solution as a function of time. The integration of each peak gave  
206 the amount of heat generated by each injection after subtracting the mannosylated  $\beta$ CD dilution  
207 heat. The best fit of the experimental data to the model of equal and independent sites provided the  
208 binding constant and the thermodynamic profile along with the corresponding standard deviations.

209 For these calculations,  $\Delta H = \Delta H^0$  was assumed and the changes in the standard free energy  $\Delta G^0$  and  
210 entropy  $\Delta S^0$  were determined as  $\Delta G^0 = -RT \ln K$  and  $T\Delta S^0 = \Delta H - \Delta G^0$ .

### 211 2.5. Synthesis of propargyl 6-*O*-benzoyl- $\alpha$ -D-mannopyranoside **4**

212 A solution of BzCN (210  $\mu$ L, 232 mg, 1.77 mmol) in dry DMF (2 mL) and catalytic amount  
213 of dry Et<sub>3</sub>N (20  $\mu$ L, 14 mg, 0.0138 mmol) were added dropwise to a solution of propargyl  $\alpha$ -D-  
214 mannopyranoside **3** (300 mg, 1.375 mmol) in dry DMF (10 mL) at -40 °C (CH<sub>3</sub>CN/dry ice bath).  
215 After 3 hours at that temperature, the reaction was quenched by adding 4 mL of MeOH and left  
216 warming up to room temperature. The solvent was rotary evaporated and the crude product was  
217 purified by column chromatography using CH<sub>2</sub>Cl<sub>2</sub>-MeOH (50:1→25:2) as eluent to yield propargyl  
218 6-*O*-benzoyl- $\alpha$ -D-mannopyranoside **4** (204 mg, 0.633 mmol, 46%) as a colorless oil.  $R_f = 0.29$   
219 (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 25:2);  $[\alpha]_D +60.8^\circ$  ( $c$  1, CH<sub>2</sub>Cl<sub>2</sub>); IR  $\nu/\text{cm}^{-1}$  3296, 2934, 1715, 1266, 1049, 712; <sup>1</sup>H-  
220 NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  (ppm) 7.99 (app dt, 2H,  $J_{app} = 6.9$  Hz,  $J_{app} = 1.5$  Hz, H<sub>Bz-2'</sub>), 7.50 (app  
221 tt, 1H,  $J_{app} = 7.3$  Hz,  $J_{app} = 1.6$  Hz, H<sub>Bz-4'</sub>), 7.38 (app tt, 2H,  $J_{app} = 7.3$  Hz,  $J_{app} = 1.6$  Hz, H<sub>Bz-3'</sub>),  
222 4.99 (d, 1H,  $^3J_{1,2} = 1.3$  Hz, H-1), 4.59 (app bd, 2H,  $J_{app} = 3.0$  Hz, H-6<sup>(a,b)</sup>), 4.22 (dd, 1H,  $^2J_{\text{CHO,CHO}} =$   
223 15.7 Hz,  $^4J_{\text{CHO,}\equiv\text{CH}} = 2.5$  Hz, CHO), 4.15 (dd, 1H,  $^2J_{\text{CHO,CHO}} = 15.7$  Hz,  $^4J_{\text{CHO,}\equiv\text{CH}} = 2.5$  Hz, CHO),  
224 4.02-3.93 (bs, 4H, H-2, OH), 3.88-3.85 (m, 3H, H-3,4,5), 2.41 (t, 1H,  $^4J_{\text{CHO,}\equiv\text{CH}} = 2.5$  Hz,  $\equiv\text{CH}$ );  
225 <sup>13</sup>C-RMN (75 MHz, CDCl<sub>3</sub>)  $\delta$  (ppm) 167.3 (CO), 133.3 (CH<sub>Bz-4'</sub>), 129.9 (CH<sub>Bz-2'</sub>), 129.8 (C<sub>Bz-1'</sub>),  
226 128.5 (CH<sub>Bz-3'</sub>), 98.7 (C-1), 78.8 (C $\equiv$ CH), 75.2 (C $\equiv$ CH), 71.5 (C-3 or C-5), 71.3 (C-3 or C-5), 70.6  
227 (C-2), 67.8 (C-4), 64.6 (C-6), 54.5 (CH<sub>2</sub>O); MALDI-TOF-MS  $m/z$  calcd for C<sub>16</sub>H<sub>18</sub>O<sub>7</sub>Na<sup>+</sup> 345.1,  
228 found 345.0 (M + Na)<sup>+</sup>;  $m/z$  calcd for C<sub>16</sub>H<sub>18</sub>O<sub>7</sub>K<sup>+</sup> 361.2, found 361.0 (M + K)<sup>+</sup>.

### 229 2.6. Synthesis of propargyl 2-*O*-acetyl-6-*O*-benzoyl- $\alpha$ -D-mannopyranoside **5**

230 Trimethyl orthoacetate (472  $\mu$ L, 445 mg, 3.7 mmol) was added at once to a solution of  
231 propargyl 6-*O*-benzoyl- $\alpha$ -D-mannopyranoside **4** (398 mg, 1.23 mmol) and camphorsulfonic acid (57  
232 mg, 0.246 mmol) in dry CH<sub>3</sub>CN (12 mL) at room temperature. After 1.5 hours the reaction was  
233 quenched with Et<sub>3</sub>N (165  $\mu$ L). The solvent was rotary evaporated at 40 °C and the colorless oily  
234 residue was dissolved in EtOAc (40 mL) and washed with 1M HCl (40 mL). The organic phase was  
235 dried over anhydrous MgSO<sub>4</sub> and solvent was rotary evaporated. The crude product was purified by  
236 column chromatography using CH<sub>2</sub>Cl<sub>2</sub>-MeOH (50:1→25:1) as eluent to yield propargyl 2-*O*-acetyl-  
237 6-*O*-benzoyl- $\alpha$ -D-mannopyranoside **5** (408 mg, 1.12 mmol, 91%) as a colorless oil.  $R_f = 0.26$   
238 (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 25:1); Mp: 113 °C;  $[\alpha]_D +43.5^\circ$  ( $c$  1, CH<sub>2</sub>Cl<sub>2</sub>); IR  $\nu/\text{cm}^{-1}$  3445, 2936, 1718, 1266,  
239 1067, 713; <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  (ppm) 8.07 (app dt, 2H,  $J_{app} = 6.9$  Hz,  $J_{app} = 1.4$  Hz, H<sub>Bz-2'</sub>  
240 2'), 7.57 (app tt, 1H,  $J_{app} = 7.4$  Hz,  $J_{app} = 1.6$  Hz, H<sub>Bz-4'</sub>), 7.44 (app tt, 2H,  $J_{app} = 7.4$  Hz,  $J_{app} = 1.4$   
241 Hz, H<sub>Bz-3'</sub>), 5.18 (dd, 1H,  $^3J_{2,3} = 3.5$  Hz,  $^3J_{1,2} = 1.6$  Hz, H-2), 5.02 (d, 1H,  $^3J_{1,2} = 1.6$  Hz, H-1), 4.71  
242 (dd, 1H,  $^2J_{6a,6b} = 12.2$  Hz,  $^3J_{5,6a} = 4.6$  Hz, H-6a), 4.55 (dd, 1H,  $^2J_{6a,6b} = 12.2$  Hz;  $^3J_{5,6b} = 2.1$  Hz, H-  
243 6b), 4.28 (dd, 1H,  $^2J_{\text{CHO,CHO}} = 15.8$  Hz,  $^4J_{\text{CHO,}\equiv\text{CH}} = 2.4$  Hz, CHO), 4.23 (dd, 1H,  $^2J_{\text{CHO,CHO}} = 15.8$   
244 Hz,  $^4J_{\text{CHO,}\equiv\text{CH}} = 2.4$  Hz, CHO), 4.08 (dd, 1H,  $^3J_{3,4} = 9.4$  Hz;  $^3J_{2,3} = 3.5$  Hz, H-3), 3.91 (ddd,  $^3J_{4,5} =$   
245 6.6 Hz,  $^3J_{5,6a} = 4.6$  Hz,  $^3J_{5,6b} = 2.1$  Hz, H-5), 3.79 (app t, 1H,  $J_{app} = 9.7$  Hz, H-4), 2.45 (t, 1H,  
246  $^4J_{\text{CHO,}\equiv\text{CH}} = 2.4$  Hz,  $\equiv\text{CH}$ ), 2.08 (s, 3H, CH<sub>3</sub>); <sup>13</sup>C-RMN (75 MHz, CDCl<sub>3</sub>)  $\delta$  (ppm) 170.9 (CO),  
247 167.2 (CO<sub>Bz</sub>), 133.5 (CH<sub>Bz-4'</sub>), 129.9 (CH<sub>Bz-2'</sub>), 129.8 (C<sub>Bz-1'</sub>), 128.6 (CH<sub>Bz-3'</sub>), 96.6 (C-1), 78.4  
248 (C $\equiv$ CH), 75.4 (C $\equiv$ CH) 71.8 (C-2), 71.3 (C-5), 69.8 (C-4), 67.8 (C-3), 63.9 (C-6), 54.9 (CH<sub>2</sub>O), 21.0  
249 (CH<sub>3</sub>). MALDI-TOF-MS  $m/z$  calcd for C<sub>18</sub>H<sub>20</sub>O<sub>8</sub>Na<sup>+</sup> 387.12, found 387.0 (M + Na)<sup>+</sup>;  $m/z$  calcd for  
250 C<sub>18</sub>H<sub>20</sub>O<sub>8</sub>K<sup>+</sup> 403.1, found 403.0 (M + K)<sup>+</sup>.

### 251 2.7. Synthesis of propargyl 2-*O*-acetyl-3,4,6-tri-*O*-benzoyl- $\alpha$ -D-mannopyranoside **6**

252 Bz<sub>2</sub>O (609 mg, 2.69 mmol), catalytic amount of Et<sub>3</sub>N (375 μL, 272 mg, 2.69 mmol) and 4-  
253 dimethylaminopyridine (4-DMAP) (2 mg, 0.015 mmol) were subsequently added to a solution of  
254 propargyl 2-*O*-acetyl-6-*O*-benzoyl- $\alpha$ -D-mannopyranoside **5** (327 mg, 0.897 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub>  
255 (17 mL). After 1.5 hours solvent was rotary evaporated and the colorless oily residue was dissolved  
256 in EtOAc (45 mL) and washed with 1M HCl (45 mL), saturated aq. NaHCO<sub>3</sub> (45 mL), and H<sub>2</sub>O (45  
257 mL). The organic phase was dried over anhydrous MgSO<sub>4</sub> and solvent was rotary evaporated. The  
258 crude product was purified by column chromatography using hexane-EtOAc (2:1) as eluent to yield  
259 propargyl 2-*O*-acetyl-3,4,6-tri-*O*-benzoyl- $\alpha$ -D-mannopyranoside **6** (491 mg, 0.858 mmol, 95%) as a  
260 colorless oil. R<sub>f</sub> = 0.63 (hexane-EtOAc 2:1); [ $\alpha$ ]<sub>D</sub> +36.5° (*c* 0.5, CH<sub>2</sub>Cl<sub>2</sub>); IR v/cm<sup>-1</sup> 2958, 1725,  
261 1267, 1108, 710. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  (ppm) 8.05 (app dt, 2H, *J*<sub>app</sub> = 6.9 Hz, *J*<sub>app</sub> = 1.5  
262 Hz, H<sub>Bz-2'</sub>), 7.95 (app dt, 2H, *J*<sub>app</sub> = 6.9 Hz, *J*<sub>app</sub> = 1.5 Hz, H<sub>Bz-2'</sub>), 7.89 (app dt, 2H, *J*<sub>app</sub> = 6.9 Hz,  
263 *J*<sub>app</sub> = 1.5 Hz, H<sub>Bz-2'</sub>), 7.58-7.46 (m, 3H, H<sub>Bz-4'</sub>), 7.44-7.32 (m, 6H, H<sub>Bz-3'</sub>), 5.94 (app t, 1H, *J*<sub>app</sub> =  
264 10.0 Hz, H-4), 5.80 (dd, 1H, <sup>3</sup>*J*<sub>3,4</sub> = 10.0 Hz, <sup>3</sup>*J*<sub>2,3</sub> = 3.3 Hz, H-3), 5.51 (dd, 1H, <sup>3</sup>*J*<sub>2,3</sub> = 3.3 Hz, <sup>3</sup>*J*<sub>1,2</sub> =  
265 1.8 Hz, H-2), 5.17 (d, 1H, <sup>3</sup>*J*<sub>1,2</sub> = 1.8 Hz, H-1), 4.63 (dd, 1H, *J*<sub>6a,6b</sub> = 11.9 Hz, *J*<sub>5,6</sub> = 2.9 Hz, H-6a),  
266 4.48 (dd, 1H, *J*<sub>6a,6b</sub> = 11.9 Hz, *J*<sub>5,6b</sub> = 5.1 Hz, H-6b), 4.44-4.39 (m, 1H, H-5), 4.38 (app d, 2H, *J*<sub>app</sub> =  
267 2.4 Hz, CH<sub>2</sub>O), 2.49 (t, 1H, <sup>4</sup>*J*<sub>CHO,≡CH</sub> = 2.4 Hz, ≡CH), 2.15 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C-RMN (75 MHz,  
268 CDCl<sub>3</sub>)  $\delta$  (ppm) 169.9 (CO), 166.3 (CO<sub>Bz</sub>), 165.7 (CO<sub>Bz</sub>), 165.6 (CO<sub>Bz</sub>), 133.8-133.3 (CH<sub>Bz-4'</sub>),  
269 130.3-129.1 (C<sub>Bz-1'</sub>, CH<sub>Bz-2'</sub>), 128.6-128.5 (CH<sub>Bz-3'</sub>), 96.4 (C-1), 78.2 (C≡), 75.2 (≡CH), 69.9 (C-  
270 2 or C-3), 69.8 (C-2 or C-3), 69.5 (C-5), 67.1 (C-4), 63.3 (C-6), 55.3 (CH<sub>2</sub>O), 20.9 (CH<sub>3</sub>). MALDI-  
271 TOF-MS *m/z* calcd for C<sub>32</sub>H<sub>28</sub>O<sub>10</sub> 572.17, found 572.9 (M)<sup>+</sup>.

## 272 2.8. Synthesis of propargyl 3,4,6-tri-*O*-benzoyl- $\alpha$ -D-mannopyranoside **7**

273 A 7% HCl in MeOH stock solution (3.14 mL) was added to a solution of propargyl 2-*O*-  
274 acetyl-3,4,6-tri-*O*-benzoyl- $\alpha$ -D-mannopyranoside **6** (85 mg, 0.148 mmol) in dry CH<sub>3</sub>CN (2 mL) and  
275 stirred for 3 days at room temperature until the disappearance of the starting material. Solvent was  
276 rotary evaporated and the light green oily residue was dissolved in EtOAc (10 mL), washed with  
277 saturated aq. NaHCO<sub>3</sub> (2x25 mL) and H<sub>2</sub>O (25 mL). The organic phase was dried over anhydrous  
278 MgSO<sub>4</sub> and solvent was rotary evaporated. The crude product was purified by column  
279 chromatography using hexane-EtOAc (3:1→5:2) as eluent to yield propargyl 3,4,6-tri-*O*-benzoyl- $\alpha$ -  
280 D-mannopyranoside **7** (64.5 mg, 0.122 mmol, 82%) as a colorless oil. R<sub>f</sub> = 0.44 (hexane-EtOAc  
281 2:1); [ $\alpha$ ]<sub>D</sub> +48.0° (*c* 1, CH<sub>2</sub>Cl<sub>2</sub>); IR v/cm<sup>-1</sup> 2955, 1723, 1452, 1266, 710. <sup>1</sup>H-NMR (300 MHz,  
282 CDCl<sub>3</sub>)  $\delta$  (ppm) 8.02 (app dt, 2H, *J*<sub>app</sub> = 6.9 Hz, *J*<sub>app</sub> = 1.5 Hz, H<sub>Bz-2'</sub>), 7.98-7.92 (m, 4H, H<sub>Bz-2'</sub>),  
283 7.56-7.45 (m, 3H, H<sub>Bz-4'</sub>), 7.42-7.30 (m, 6H, H<sub>Bz-3'</sub>), 5.97 (app t, 1H, *J*<sub>app</sub> = 10.0 Hz, H-4), 5.68  
284 (dd, 1H, <sup>3</sup>*J*<sub>3,4</sub> = 10.0 Hz, <sup>3</sup>*J*<sub>2,3</sub> = 3.2 Hz, H-3), 5.21 (d, 1H, <sup>3</sup>*J*<sub>1,2</sub> = 1.7 Hz, H-1), 4.59 (dd, 1H, <sup>2</sup>*J*<sub>6a,6b</sub> =  
285 12.0 Hz, <sup>3</sup>*J*<sub>5,6</sub> = 3.1 Hz, H-6a), 4.49 (dd, 1H, <sup>2</sup>*J*<sub>6a,6b</sub> = 12.0 Hz, *J*<sub>5,6</sub> = 5.2 Hz, H-6b), 4.40 (dd, 1H,  
286 <sup>3</sup>*J*<sub>2,3</sub> = 3.2 Hz, <sup>3</sup>*J*<sub>1,2</sub> = 1.7 Hz, H-2), 4.38 (app d, 2H, *J*<sub>app</sub> = 2.4 Hz, CH<sub>2</sub>O), 4.36-4.34 (m, 1H, H-5),  
287 2.49 (t, 1H, <sup>4</sup>*J*<sub>CHO,≡CH</sub> = 2.4 Hz, ≡CH); <sup>13</sup>C-RMN (75 MHz, CDCl<sub>3</sub>)  $\delta$  (ppm) 166.4-165.6 (CO<sub>Bz</sub>),  
288 133.5-133.2 (CH<sub>Bz-4'</sub>), 130.1-129.2 (C<sub>Bz-1'</sub>, CH<sub>Bz-2'</sub>), 128.7-128.6 (CH<sub>Bz-3'</sub>), 98.4 (C-1), 78.9  
289 (C≡), 75.5 (≡CH), 72.6 (C-2), 69.4 (C-3 or C-5), 69.3 (C-3 or C-5), 67.0 (C-4), 63.5 (C-6), 55.1  
290 (CH<sub>2</sub>O). MALDI-TOF-MS *m/z* calcd for C<sub>30</sub>H<sub>26</sub>O<sub>9</sub>Na<sup>+</sup> 553.16, found 553.1 (M+Na)<sup>+</sup>.

## 291 2.9. Synthesis of propargyl *O*-(2,3,4,6-tetra-*O*-benzoyl- $\alpha$ -D-mannopyranosyl)-(1→2)-3,4,6-tri-*O*- 292 benzoyl- $\alpha$ -D-mannopyranoside **9**

293 A mixture of propargyl 3,4,6-tri-*O*-benzoyl- $\alpha$ -D-mannopyranoside **7** (140 mg, 0.264 mmol)  
294 and 2,3,4,6-tetra-*O*-benzoyl- $\alpha$ -D-mannopyranosyl trichloroacetimidate **8** (240 mg, 0.325 mmol) was

295 co-evaporated three times from toluene and the white residue dried under vacuum in the presence of  
296 4 Å molecular sieves for 1.5 h. The mixture was dissolved in dry CH<sub>2</sub>Cl<sub>2</sub> (9.5 mL) and stirred at 0  
297 °C for 15 min. A catalytic amount of TMSOTf (9.6 μL, 0.0528 mmol) was added and stirred at 0 °C  
298 for 2 h. Et<sub>3</sub>N (100 μL) was added, and the mixture was filtered over a pad of Celite (1.5 cm).  
299 Solvent was rotary evaporated and the crude product was purified by column chromatography using  
300 CH<sub>2</sub>Cl<sub>2</sub>-MeOH (500:1→200:1) to yield propargyl *O*-(2,3,4,6-tetra-*O*-benzoyl- $\alpha$ -D-  
301 mannopyranosyl)-(1→2)-3,4,6-tri-*O*-benzoyl- $\alpha$ -D-mannopyranoside **9** (150 mg, 0.135 mmol, 51%)  
302 as a white foamy solid. R<sub>f</sub> = 0.54 (hexane-EtOAc 2:1); Mp 121 °C; [ $\alpha$ ]<sub>D</sub> -28.5° (*c* 1, CH<sub>2</sub>Cl<sub>2</sub>); IR  
303 v/cm<sup>-1</sup> 2957, 1724, 1264, 1107, 708. <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  (ppm) 8.10-8.08 (m, 4H, H<sub>Bz</sub>-  
304 2'), 8.03 (app dd, 2H, *J*<sub>app</sub> = 8.4 Hz, *J*<sub>app</sub> = 1.2 Hz, H<sub>Bz</sub>-2'), 7.98 (app dd, 2H, *J*<sub>app</sub> = 8.4 Hz, *J*<sub>app</sub> =  
305 1.2 Hz, H<sub>Bz</sub>-2'), 7.95 (app dd, 2H, *J*<sub>app</sub> = 8.4 Hz, *J*<sub>app</sub> = 1.2 Hz, H<sub>Bz</sub>-2'), 7.93 (app dd, 2H, *J*<sub>app</sub> = 8.4  
306 Hz, *J*<sub>app</sub> = 1.2 Hz, H<sub>Bz</sub>-2'), 7.87 (app dd, 2H, *J*<sub>app</sub> = 8.4 Hz, *J*<sub>app</sub> = 1.2 Hz, H<sub>Bz</sub>-2'), 7.60-7.43 (m, 7H,  
307 H<sub>Bz</sub>-4'), 7.42-7.28 (m, 14H, H<sub>Bz</sub>-3'), 6.12 (app t, 1H, *J*<sub>app</sub> = 10.1 Hz, H-4<sup>B</sup>), 6.04 (app t, 1H, *J*<sub>app</sub> =  
308 9.9 Hz, H-4<sup>A</sup>), 6.02 (dd, 1H, <sup>3</sup>*J*<sub>3B,4B</sub> = 10.1 Hz, <sup>3</sup>*J*<sub>2B,3B</sub> = 3.3 Hz, H-3<sup>B</sup>), 5.91 (dd, 1H, <sup>3</sup>*J*<sub>2B,3B</sub> = 3.3  
309 Hz, <sup>3</sup>*J*<sub>1B,2B</sub> = 1.7 Hz, H-2<sup>B</sup>), 5.90 (dd, 1H, <sup>3</sup>*J*<sub>2A,3A</sub> = 3.1 Hz, <sup>3</sup>*J*<sub>3A,4A</sub> = 9.9 Hz, H-3<sup>A</sup>), 5.41 (d, 1H,  
310 <sup>3</sup>*J*<sub>1A,2A</sub> = 2.0 Hz, H-1<sup>A</sup>), 5.28 (d, 1H, <sup>3</sup>*J*<sub>1B,2B</sub> = 1.7 Hz, H-1<sup>B</sup>), 4.71 (dd, 1H, <sup>2</sup>*J*<sub>6B(a,b)</sub> = 12.2 Hz,  
311 <sup>3</sup>*J*<sub>5B,6Ba</sub> = 2.7 Hz, H-6<sup>Ba</sup>), 4.65 (dd, 1H, <sup>2</sup>*J*<sub>6A(a,b)</sub> = 12.2 Hz, <sup>3</sup>*J*<sub>5A,6Aa</sub> = 3.0 Hz, H-6<sup>Aa</sup>), 4.61 (ddd, 1H,  
312 <sup>3</sup>*J*<sub>4B,5B</sub> = 10.0 Hz, <sup>3</sup>*J*<sub>5B,6Bb</sub> = 4.4 Hz, <sup>3</sup>*J*<sub>5B,6Ba</sub> = 2.7 Hz, H-5<sup>B</sup>), 4.57 (dd, 1H, <sup>2</sup>*J*<sub>6A(a,b)</sub> = 12.2 Hz,  
313 <sup>3</sup>*J*<sub>5A,6Ab</sub> = 5.3 Hz, H-6<sup>Ab</sup>), 4.47 (dd, 1H, <sup>2</sup>*J*<sub>6B(a,b)</sub> = 12.2 Hz, <sup>3</sup>*J*<sub>5B,6Bb</sub> = 4.4 Hz, H-6<sup>Bb</sup>), 4.43 (ddd, 1H,  
314 <sup>3</sup>*J*<sub>4A,5A</sub> = 10.0 Hz, <sup>3</sup>*J*<sub>5A,6Ab</sub> = 5.3 Hz, <sup>3</sup>*J*<sub>5A,6Aa</sub> = 3.0 Hz, H-5<sup>A</sup>), 4.41 (dd, 1H, <sup>3</sup>*J*<sub>2A,3A</sub> = 3.1 Hz, <sup>3</sup>*J*<sub>1A,2A</sub> =  
315 2.0 Hz, H-2<sup>A</sup>), 4.34 (dd, 1H, <sup>2</sup>*J*<sub>CHO,CHO</sub> = 15.8 Hz, <sup>4</sup>*J*<sub>CHO,≡CH</sub> = 2.4 Hz, CHO), 4.29 (dd, 1H,  
316 <sup>2</sup>*J*<sub>CHO,CHO</sub> = 15.8 Hz, <sup>4</sup>*J*<sub>CHO,≡CH</sub> = 2.4 Hz, CHO), 2.52 (t, 1H, <sup>4</sup>*J*<sub>CHO,≡C</sub> = 2.4 Hz, ≡CH); <sup>13</sup>C-RMN  
317 (150 MHz, CDCl<sub>3</sub>)  $\delta$  (ppm) 166.5-165.0 (CO), 133.6-133.2 (CH<sub>Bz</sub>-4'), 130.2-129.8 (CH<sub>Bz</sub>-2'),  
318 129.3-129.0 (C<sub>Bz</sub>-1'), 128.7-128.5 (CH<sub>Bz</sub>-3'), 99.8 (C-1<sup>B</sup>), 97.5 (C-1<sup>A</sup>), 78.3 (C≡), 76.9 (C-2<sup>A</sup>  
319 overlapped with CDCl<sub>3</sub> signal), 75.9 (≡CH), 70.6 (C-3<sup>A</sup>), 70.2 (C-2<sup>B</sup>), 69.9 (C-5<sup>B</sup>), 69.8 (C-3<sup>B</sup>),  
320 69.6 (C-5<sup>A</sup>), 67.7 (C-4<sup>A</sup>), 66.9 (C-4<sup>B</sup>), 63.7 (C-6<sup>A</sup>), 62.9 (C-6<sup>B</sup>), 55.3 (CH<sub>2</sub>O). MALDI-TOF-MS  
321 *m/z* calcd for C<sub>64</sub>H<sub>52</sub>O<sub>18</sub>Na<sup>+</sup> 1131.3, found 1131.1 (M+Na)<sup>+</sup>; calcd for C<sub>64</sub>H<sub>52</sub>O<sub>18</sub>K<sup>+</sup> 1147.3, found  
322 1147.1 (M+K)<sup>+</sup>

## 323 2.10. Synthesis of propargyl $\alpha$ -D-mannopyranosyl-(1→2)- $\alpha$ -D-mannopyranoside **10**

324 Propargyl *O*-(2,3,4,6-tetra-*O*-benzoyl- $\alpha$ -D-mannopyranosyl)-(1→2)-3,4,6-tri-*O*-benzoyl- $\alpha$ -  
325 D-mannopyranoside **9** (3.14 g, 0.0028 mol) was sonicated in dry MeOH (188 mL) until a clear  
326 solution was formed. Then, NaOMe in dry MeOH was added until pH 12 and the mixture was  
327 stirred for 4 hours. The pH was neutralized with 0.1N HCl and solvent was rotary evaporated. The  
328 crude product was purified by column chromatography using EtOAc-MeOH (3:2) as eluent to give  
329 propargyl  $\alpha$ -D-mannopyranosyl-(1→2)- $\alpha$ -D-mannopyranoside **10** (1 g, 94%) as an hygroscopic  
330 white powder after lyophilization. R<sub>f</sub> = 0.54 (EtOAc-MeOH 1:1); [ $\alpha$ ]<sub>D</sub> +49.3° (*c* 1, H<sub>2</sub>O); IR v/cm<sup>-1</sup>  
331 3332, 2945, 1727, 1449, 1022. <sup>1</sup>H-RMN (600 MHz, D<sub>2</sub>O)  $\delta$  (ppm) 5.27 (d, 1H, <sup>3</sup>*J*<sub>1A,2A</sub> = 1.7 Hz, H-  
332 1<sup>A</sup>), 5.02 (d, 1H, <sup>3</sup>*J*<sub>1B,2B</sub> = 1.8 Hz, H-1<sup>B</sup>), 4.36 (dd, 1H, <sup>2</sup>*J*<sub>CHO,CHO</sub> = 16.0 Hz, <sup>4</sup>*J*<sub>CHO,≡CH</sub> = 2.4 Hz,  
333 CHO), 4.29 (dd, 1H, <sup>2</sup>*J*<sub>CHO,CHO</sub> = 16.0 Hz, <sup>4</sup>*J*<sub>CHO,≡CH</sub> = 2.4 Hz, CHO), 4.08 (dd, 1H, <sup>3</sup>*J*<sub>2B,3B</sub> = 3.3 Hz,  
334 <sup>3</sup>*J*<sub>1B,2B</sub> = 1.8 Hz, H-2<sup>B</sup>), 3.97 (dd, 1H, <sup>3</sup>*J*<sub>2A,3A</sub> = 3.4 Hz, <sup>3</sup>*J*<sub>1A,2A</sub> = 1.7 Hz, H-2<sup>A</sup>), 3.94-3.81 (m, 4H, H-  
335 3<sup>A,B</sup>, 6<sup>A(a,b)</sup>), 3.80-3.69 (m, 4H, H-4<sup>A</sup>, 5<sup>B</sup>, 6<sup>B(a,b)</sup>), 3.66-3.58 (m, 2H, H-4<sup>B</sup>, 5<sup>A</sup>), 2.91 (t, 1H, <sup>4</sup>*J*<sub>CHO,≡CH</sub>  
336 = 2.4 Hz, ≡CH); <sup>13</sup>C-RMN (150 MHz, D<sub>2</sub>O)  $\delta$  (ppm) 102.4 (C-1<sup>B</sup>), 97.0 (C-1<sup>A</sup>), 78.8 (C≡), 78.7 (C-  
337 2<sup>A</sup>), 76.2 (≡CH), 73.2 (C-5<sup>A</sup>), 73.1 (C-5<sup>B</sup>), 70.3 (C-3<sup>B</sup>), 70.0 (C-2<sup>B</sup>), 69.9 (C-3<sup>A</sup>), 66.8 (C-4<sup>B</sup>), 66.7



338 (C-4<sup>A</sup>), 61.0 (C-6<sup>A</sup>), 60.7 (C-6<sup>B</sup>), 54.5 (CH<sub>2</sub>O). ESI<sup>+</sup> *m/z* calcd for C<sub>15</sub>H<sub>24</sub>O<sub>11</sub>Na<sup>+</sup> 403.13 found  
339 403.51.

340 *2.11. Synthesis of 6<sup>l</sup>-deoxy-6<sup>l</sup>-[4-( $\alpha$ -D-mannopyranosyloxymethyl)-1H-1,2,3-triazol-1-yl]-6<sup>X</sup>-deoxy-*  
341 *6<sup>X</sup>-N-{3'-[N'-(4''-nitro-3''-trifluoromethylphen-1''-yl)amino]propylamino}cyclomaltoheptaose*  
342 ***ManNOPD $\beta$ CD***

343 A suspension of CuI (9.5 mg, 0.05 mmol) in H<sub>2</sub>O (15 mL) was added to a pre-heated (90 °C)  
344 solution of propargyl  $\alpha$ -D-mannoside **3** (46.6 mg, 0.213 mmol) and 6<sup>l</sup>-deoxy-6<sup>l</sup>-azido-6<sup>X</sup>-deoxy-6<sup>X</sup>-  
345 *N*-{3-[N'-(4'-nitro-3'-trifluoromethylphen-1'-yl)amino]propylamino}cyclomaltoheptaose **1** (200  
346 mg, 0.142 mmol) in DMF (15 mL). The mixture was stirred for 2 h at 100 °C and overnight at rt.  
347 Solvents were evaporated under high vacuum and the crude product was purified by column  
348 chromatography using CH<sub>3</sub>CN-H<sub>2</sub>O-(30% v/v aq. NH<sub>3</sub>) (20:5:2→10:5:1) as eluent. The obtained  
349 material was dialyzed to yield **ManNOPD $\beta$ CD** (160 mg, 0.099 mmol, 71 %) as a light-sensitive  
350 yellow solid. R<sub>f</sub> = 0.42 (CH<sub>3</sub>CN-H<sub>2</sub>O-(30% v/v aq. NH<sub>3</sub>) 10:5:1); IR (KBr) v/cm<sup>-1</sup> 3386, 2929,  
351 1612, 1330, 1156, 1031. <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  (ppm) 8.31-8.22 (m, H<sup>ar</sup>), 8.15-8.11 (m,  
352 H<sup>ar</sup>), 8.06 (s, H-5-C<sub>2</sub>HN<sub>3</sub>), 6.95-6.90 (m, H<sup>ar</sup>), 6.82-6.73 (bs, NH), 5.38-4.53 (m, H-1<sup>I,X,CD,A</sup>, 6<sup>I(a,b)</sup>,  
353 CH<sub>2</sub>O, overlapped with HDO), 4.29-3.16 (m, H-2<sup>I,X,CD,A</sup>, 3<sup>I,X,CD,A</sup>, 4<sup>I,X,CD,A</sup>, 5<sup>I,X,CD,A</sup>, 6<sup>CD(a,b),A(a,b)</sup>,  
354 CH<sub>2</sub>NHPh), 3.11-2.45 (m, H-6<sup>X(a,b)</sup>, CH<sub>2</sub>NH), 1.86-1.70 (m, CH<sub>2</sub>). <sup>13</sup>C-NMR (150 MHz, CDCl<sub>3</sub>)  $\delta$   
355 (ppm) 152.4 (C<sup>ar</sup>), 143.5-143.4 (C-4-C<sub>2</sub>HN<sub>3</sub>), 134.9 (C<sup>ar</sup>), 130.0 (C<sup>ar</sup>), 127.3-126.5 (C-5-C<sub>2</sub>HN<sub>3</sub>,  
356 C<sup>ar</sup>), 122.3 (q, <sup>1</sup>J<sub>C,F</sub> = 270.9 Hz, CF<sub>3</sub>), 111.3 (C<sup>ar</sup>), 102.8-101.5 (C-1<sup>I,X,CD</sup>), 99.9-99.4 (C-1<sup>CD,A</sup>),  
357 94.0-93.7 (C-1<sup>CD</sup>), 84.0-80.9 (C-4<sup>I,X,CD</sup>), 73.1-70.0 (C-2<sup>I,X,CD,A</sup>, 3<sup>I,X,CD,A</sup>, 5<sup>I,X,CD,A</sup>), 66.8-66.7 (C-4<sup>A</sup>),  
358 60.9-58.6 (C-6<sup>CD,A</sup>, CH<sub>2</sub>O), 51.3-50.7 (C-6<sup>I,X</sup>), 44.8 (CH<sub>2</sub>NH), 40.6 (CH<sub>2</sub>NHPh), 26.0 (CH<sub>2</sub>). ESI<sup>+</sup>  
359 *m/z* calcd for C<sub>61</sub>H<sub>94</sub>F<sub>3</sub>N<sub>6</sub>O<sub>41</sub><sup>+</sup> 1624.4 found 1624.5 (M+H)<sup>+</sup>.

360 *2.12. Synthesis of 6<sup>l</sup>-deoxy-6<sup>l</sup>-[4-( $\alpha$ -D-mannopyranosyl-(1→2)- $\alpha$ -D-mannopyranosiloxymethyl)-1H-*  
361 *1,2,3-triazol-1-yl]-6<sup>X</sup>-deoxy-6<sup>X</sup>-N-{3'-[N'-(4''-nitro-3''-trifluoromethylphen-1''-*  
362 *yl)amino]propylamino}cyclomaltoheptaose **BiManNOPD $\beta$ CD***

363 A suspension of CuI (5.9 mg, 0.031 mmol) in H<sub>2</sub>O (9.2 mL) was added to a pre-heated  
364 solution (90 °C) of propargyl  $\alpha$ -D-mannopyranosyl-(1→2)- $\alpha$ -D-mannopyranoside **10** (50 mg, 0.131  
365 mmol) and 6<sup>l</sup>-deoxy-6<sup>l</sup>-azido-6<sup>X</sup>-deoxy-6<sup>X</sup>-*N*-{3-[N'-(4'-nitro-3'-trifluoromethylphen-1'-  
366 yl)amino]propylamino}cyclomaltoheptaose **1** (123 mg, 0.088 mmol) in DMF (9.2 mL). The  
367 mixture was stirred for 2 hours at 100 °C and overnight at rt. Solvents were evaporated under high  
368 vacuum and the crude product was purified by column chromatography using CH<sub>3</sub>CN-H<sub>2</sub>O-(30%  
369 v/v aq. NH<sub>3</sub>) (10:5:1→20:15:2) as eluent. The obtained material was dialyzed to yield  
370 **BiManNOPD $\beta$ CD** (49 mg, 0.027 mmol, 88%) as a light-sensitive yellow solid. R<sub>f</sub> = 0.29 (CH<sub>3</sub>CN-  
371 H<sub>2</sub>O-(30% v/v aq. NH<sub>3</sub>) 10:5:1); IR (KBr) v/cm<sup>-1</sup> 3416, 2927, 1612, 1329, 1155, 1032. <sup>1</sup>H-NMR  
372 (600 MHz, CDCl<sub>3</sub>)  $\delta$  (ppm) 8.32-8.22 (m, H<sup>ar</sup>), 8.16-8.11 (m, H<sup>ar</sup>), 8.06 (s, H-5-C<sub>2</sub>HN<sub>3</sub>), 6.97-6.90  
373 (m, H<sup>ar</sup>), 6.83-6.78 (bs, NH), 5.40-4.53 (m, H-1<sup>I,X,CD,A,B</sup>, 6<sup>I(a,b)</sup>, CH<sub>2</sub>O, overlapped with HDO), 4.26-  
374 3.17 (m, H-2<sup>I,X,CD,A,B</sup>, 3<sup>I,X,CD,A,B</sup>, 4<sup>I,X,CD,A,B</sup>, 5<sup>I,X,CD,A,B</sup>, 6<sup>X(a,b),CD(a,b),A(a,b),B(a,b)</sup>, CH<sub>2</sub>NHPh), 3.11-2.45 (m,  
375 H-6<sup>X(a,b)</sup>, CH<sub>2</sub>NH), 1.86-1.70 (m, CH<sub>2</sub>). <sup>13</sup>C-NMR (150 MHz, CDCl<sub>3</sub>)  $\delta$  (ppm) 153.8-153.1 (C<sup>ar</sup>),  
376 144.2-143.9 (C-4-C<sub>2</sub>HN<sub>3</sub>), 135.5 (C<sup>ar</sup>), 130.7 (C<sup>ar</sup>), 127.9-127.0 (C-5-C<sub>2</sub>-HN<sub>3</sub>, C<sup>ar</sup>), 123.5 (q, <sup>1</sup>J<sub>C,F</sub> =  
377 273.4 Hz, CF<sub>3</sub>), 111.9 (C<sup>ar</sup>), 103.4-102.0 (C-1<sup>I,X,CD,B</sup>), 99.1-98.6 (C-1<sup>CD,A</sup>), 93.2 (C-1<sup>CD</sup>), 84.7-79.2  
378 (C-2<sup>A</sup>, 4<sup>I,X,CD</sup>), 73.9-70.6 (C-2<sup>I,X,CD,A,B</sup>, 3<sup>I,X,CD,A,B</sup>, 5<sup>I,X,CD,A,B</sup>), 67.7-67.5 (C-4<sup>A,B</sup>), 61.7-59.3 (C-6<sup>CD,A,B</sup>,  
379 CH<sub>2</sub>O), 52.0-51.9 (C-6<sup>I,X</sup>), 47.9-45.4 (CH<sub>2</sub>NH), 41.7-41.1 (CH<sub>2</sub>NHPh), 26.3 (CH<sub>2</sub>). ESI<sup>+</sup> *m/z* calcd  
380 for C<sub>67</sub>H<sub>104</sub>F<sub>3</sub>N<sub>6</sub>O<sub>46</sub><sup>+</sup> 1786.6 found 1786.6 (M+H)<sup>+</sup>.

381 2.13. Synthesis of 6<sup>I</sup>-deoxy-6<sup>I</sup>-[4-( $\alpha$ -D-mannopyranosyloxymethyl)-1*H*-1,2,3-triazol-1-  
382 yl]cyclomaltoheptaose **Man $\beta$ CD**

383 Compound **Man $\beta$ CD** was prepared by modifying a previously reported method (Gade et al.,  
384 2016). CuI (0.057 g, 0.302 mmol) was added to a preheated (100 °C) solution of 6<sup>I</sup>-azide-6<sup>I</sup>-  
385 deoxycyclomaltoheptaose **2** (1 g, 0.862 mmol) and propargyl  $\alpha$ -D-mannoside **3** (0.282 g, 1.292  
386 mmol) in a mixture of DMF (75 mL) and water (75 mL). After 16 hours at that temperature, the  
387 solvent was rotary evaporated and the crude product was purified by column chromatography using  
388 CH<sub>3</sub>CN-H<sub>2</sub>O-(30% v/v aq. NH<sub>3</sub>) 20:15:2 as eluent to yield 6<sup>I</sup>-deoxy-6<sup>I</sup>-[4-( $\alpha$ -D-  
389 mannopyranosyloxymethyl)-1*H*-1,2,3-triazol-1-yl]cyclomaltoheptaose **Man $\beta$ CD** (1.093 g, 0.793  
390 mmol, 92 %) as a white solid. R<sub>f</sub> = 0.41 (CH<sub>3</sub>CN-H<sub>2</sub>O-(30% v/v aq. NH<sub>3</sub>) 20:15:2); Mp 233 °C  
391 (dec); [ $\alpha$ ]<sub>D</sub> +114.2° (c 1, H<sub>2</sub>O); IR (KBr) v/cm<sup>-1</sup> 3387, 2928, 1641, 1412, 1156, 1029, 581; <sup>1</sup>H-RMN  
392 (600 MHz, D<sub>2</sub>O)  $\delta$  (ppm) 8.14 (s, 1H, H-5-C<sub>2</sub>HN<sub>3</sub>), 5.20 (d, 1H, <sup>3</sup>J<sub>1,2</sub> = 3.8 Hz, H-1<sup>VII</sup>), 5.10-5.08  
393 (m, 4H, H-1<sup>III-VI</sup>), 5.05 (bd, 1H, <sup>2</sup>J<sub>6a,6b</sub> = 14.6 Hz, H-6<sup>Ia</sup>), 5.03 (d, 1H, <sup>3</sup>J<sub>1,2</sub> = 3.8 Hz, H-1<sup>II</sup>), 5.02 (d,  
394 1H, <sup>3</sup>J<sub>1,2</sub> = 1.6 Hz, H-1<sup>A</sup>), 5.01 (d, 1H, <sup>3</sup>J<sub>1,2</sub> = 3.6 Hz, H-1<sup>I</sup>), 4.86 (bd, 1H, <sup>2</sup>J = 12.1 Hz, CH<sup>a</sup>O), 4.69  
395 (bd, 1H, <sup>2</sup>J = 12.1 Hz, CH<sup>b</sup>O), 4.65 (dd, 1H, <sup>2</sup>J<sub>6a,6b</sub> = 14.6 Hz, <sup>3</sup>J<sub>5,6b</sub> = 9.4 Hz, H-6<sup>Ib</sup>), 4.25 (t, 1H, J =  
396 9.5 Hz, H-5<sup>I</sup>), 4.03 (t, 1H, J = 9.6 Hz, H-3<sup>VII</sup>), 4.02-3.96 (m, 8H, H-2<sup>A</sup>, 3<sup>I,III-VI</sup>, 5<sup>VII</sup>), 3.95-3.85 (m,  
397 17H, H-3<sup>II</sup>, 5<sup>III-VII</sup>, 6<sup>(III-VII)(a,b)</sup>, 6<sup>Aa</sup>), 3.81-3.79 (m, 3H, H-3<sup>A</sup>, 5<sup>A</sup>, 6<sup>Ab</sup>), 3.72 (dd, 1H, <sup>3</sup>J<sub>2,3</sub> = 10.1 Hz, <sup>3</sup>J<sub>1,2</sub>  
398 = 3.8 Hz, H-2<sup>VII</sup>), 3.70-3.66 (m, 6H, H-2<sup>I,III-VI</sup>, 4<sup>A</sup>), 3.65-3.59 (m, 6H, H-2<sup>II</sup>, 4<sup>III-VII</sup>), 3.58-3.53 (m,  
399 3H, H-4<sup>I,II</sup>, 5<sup>II</sup>), 3.18 (bd, 1H, <sup>2</sup>J<sub>6a,6b</sub> = 12.3 Hz, H-6<sup>Ia</sup>), 2.83 (bd, 1H, <sup>2</sup>J<sub>6a,6b</sub> = 12.3 Hz, H-6<sup>Ib</sup>); <sup>13</sup>C-  
400 RMN (150 MHz, D<sub>2</sub>O)  $\delta$  (ppm) 143.4 (C-4-C<sub>2</sub>HN<sub>3</sub>), 126.8 (C-5-C<sub>2</sub>HN<sub>3</sub>), 102.0 (C-1<sup>VII</sup>), 101.9-  
401 101.8 (C-1<sup>II-VI</sup>), 101.4 (C-1<sup>I</sup>), 99.5 (C-1<sup>A</sup>), 83.1 (C-4<sup>I</sup>), 81.2-80.6 (C-4<sup>II-VII</sup>), 73.0-71.5 (C-2<sup>I-VII</sup>, 3<sup>I</sup>-  
402 <sup>VII</sup>, 5<sup>II-VII,A</sup>), 70.5 (C-3<sup>A</sup>), 70.4 (C-5<sup>I</sup>), 70.0 (C-2<sup>A</sup>), 66.6 (C-4<sup>A</sup>), 60.9 (C-6<sup>A</sup>), 60.3-60.2 (C-6<sup>III-VII</sup>),  
403 59.6 (CH<sub>2</sub>O), 59.2 (C-6<sup>II</sup>), 51.2 (C-6<sup>I</sup>); MALDI-TOF-MS *m/z* calcd for C<sub>51</sub>H<sub>83</sub>N<sub>3</sub>O<sub>40</sub>Na<sup>+</sup> 1400.4,  
404 found 1400.2 (M + Na)<sup>+</sup>.

405 2.14. Synthesis of 6<sup>I</sup>-deoxy-6<sup>I</sup>-[4-( $\alpha$ -D-mannopyranosyl-(1 $\rightarrow$ 2)- $\alpha$ -D-mannopyranosyloxymethyl)-1*H*-  
406 1,2,3-triazol-1-yl]cyclomaltoheptaose **BiMan $\beta$ CD**

407 CuI (0.006 g, 0.030 mmol) was added to a preheated (100 °C) solution of 6<sup>I</sup>-azide-6<sup>I</sup>-  
408 deoxycyclomaltoheptaose **2** (0.100 g, 0.086 mmol) and propargyl  $\alpha$ -D-mannopyranosyl-(1 $\rightarrow$ 2)- $\alpha$ -  
409 D-mannopyranoside **10** (0.050 g, 0.131 mmol) in a mixture of DMF (7.5 mL) and water (7.5 mL).  
410 After 16 hours at that temperature, the solvent was rotary evaporated and the crude product was  
411 purified by column chromatography using CH<sub>3</sub>CN-H<sub>2</sub>O-(30% v/v aq. NH<sub>3</sub>) 20:15:2 as eluent to  
412 yield 6<sup>I</sup>-deoxy-6<sup>I</sup>-[4-( $\alpha$ -D-mannopyranosyl-(1 $\rightarrow$ 2)- $\alpha$ -D-mannopyranosyloxymethyl)-1*H*-1,2,3-  
413 triazol-1-yl]cyclomaltoheptaose **BiMan $\beta$ CD** (0.119 g, 0.077 mol, 90 %) as a white solid. R<sub>f</sub> = 0.24  
414 (CH<sub>3</sub>CN-H<sub>2</sub>O-(30% v/v aq. NH<sub>3</sub>) 20:15:2); Mp 219 °C (dec); [ $\alpha$ ]<sub>D</sub> +106.1° (c 1, H<sub>2</sub>O); IR (KBr)  
415 v/cm<sup>-1</sup> 3386, 2929, 1658, 1412, 1155, 1079, 1031, 472; <sup>1</sup>H-RMN (500 MHz, D<sub>2</sub>O)  $\delta$  (ppm) 8.09 (s,  
416 1H, H-5-C<sub>2</sub>HN<sub>3</sub>), 5.21 (d, 1H, <sup>3</sup>J<sub>1,2</sub> = 1.5 Hz, H-1<sup>A</sup>), 5.17 (d, 1H, <sup>3</sup>J<sub>1,2</sub> = 3.8 Hz, H-1<sup>VII</sup>), 5.07-5.05  
417 (m, 4H, H-1<sup>III-VI</sup>), 5.03 (dd, 1H, <sup>2</sup>J<sub>6a,6b</sub> = 14.6 Hz, <sup>3</sup>J<sub>5,6a</sub> = 1.5 Hz, H-6<sup>Ia</sup>), 5.00-4.99 (m, 2H, H-1<sup>II,B</sup>),  
418 4.97 (d, 1H, <sup>3</sup>J<sub>1,2</sub> = 3.7 Hz, H-1<sup>I</sup>), 4.83 (d, 1H, <sup>2</sup>J = 12.3 Hz, CH<sup>a</sup>O, overlapped with HDO), 4.66 (d,  
419 1H, <sup>2</sup>J = 12.3 Hz, CH<sup>b</sup>O), 4.61 (dd, 1H, <sup>2</sup>J<sub>6a,6b</sub> = 14.6 Hz, <sup>3</sup>J<sub>5,6b</sub> = 9.4 Hz, H-6<sup>Ib</sup>), 4.21 (dt, <sup>3</sup>J = 9.7  
420 Hz, <sup>3</sup>J = 1.3 Hz, H-5<sup>I</sup>), 4.05 (dd, 1H, <sup>3</sup>J<sub>2,3</sub> = 3.3 Hz, <sup>3</sup>J<sub>1,2</sub> = 1.8 Hz, H-2<sup>B</sup>), 4.03-3.92 (m, 8H, H-  
421 2<sup>A</sup>, 3<sup>I,III-VII</sup>, 5<sup>VII</sup>), 3.90-3.81 (18H, H-3<sup>II,A,B</sup>, 4<sup>B</sup>, 5<sup>III-VI</sup>, 6<sup>(III-VII)(a,b)</sup>), 3.77-3.63 (m, 9H, H-2<sup>I,III</sup>-  
422 <sup>VII</sup>, 4<sup>A</sup>, 6<sup>A(a,b)</sup>), 3.63-3.54 (m, 9H, H-2<sup>II</sup>, 4<sup>III-VII</sup>, 5<sup>A</sup>, 6<sup>B(a,b)</sup>), 3.54 (t, 1H, <sup>3</sup>J = 10.1 Hz, H-4<sup>I</sup>), 3.50-3.48  
423 (m, 3H, H-4<sup>II,5II,B</sup>), 3.14 (d, 1H, <sup>3</sup>J<sub>6a,6b</sub> = 11.2 Hz, H-6<sup>Ia</sup>), 2.78 (d, 1H, <sup>3</sup>J<sub>6a,6b</sub> = 11.2 Hz, H-6<sup>Ib</sup>); <sup>13</sup>C-  
424 RMN (125 MHz, D<sub>2</sub>O)  $\delta$  (ppm) 143.4 (C-4-C<sub>2</sub>HN<sub>3</sub>), 126.8 (C-5-C<sub>2</sub>HN<sub>3</sub>), 102.3 (C-1<sup>B</sup>), 102.0 (C-



425 1<sup>VII</sup>), 101.9-101.8 (C-1<sup>II-VI</sup>), 101.3 (C-1<sup>I</sup>), 97.9 (C-1<sup>A</sup>), 83.0 (C-4<sup>I</sup>), 81.2-81.0 (C-4<sup>III-VII</sup>), 80.6 (C-  
426 4<sup>II</sup>), 78.6 (C-2<sup>A</sup>), 73.2-71.7 (C-2<sup>I-VII</sup>, 3<sup>I-VII</sup>, 5<sup>III-VII,A,B</sup>), 71.4 (C-5<sup>II</sup>), 70.5 (C-5<sup>I</sup>), 70.2 (C-3<sup>B</sup>), 70.1 (C-  
427 3<sup>A</sup>), 69.9 (C-2<sup>B</sup>), 66.8 (C-4<sup>A</sup>), 66.7 (C-4<sup>B</sup>), 61.0 (C-6<sup>B</sup>), 60.8 (C-6<sup>A</sup>), 60.3 (C-6<sup>VII</sup>), 60.2 (C-6<sup>III-VI</sup>),  
428 59.8 (CH<sub>2</sub>O), 59.1 (C-6<sup>II</sup>), 51.2 (C-6<sup>I</sup>); MALDI-TOF-MS *m/z* calcd for C<sub>57</sub>H<sub>93</sub>N<sub>3</sub>O<sub>45</sub>Na<sup>+</sup> 1562.5,  
429 found 1562.2 (M + Na)<sup>+</sup>.

430

### 431 3. Results and discussion

#### 432 3.1. Synthesis

433 In order to introduce the NOPD 3-(trifluoromethyl)-4-nitrobenzenamine along with a  
434 mannose or  $\alpha(1\rightarrow2)$ mannobioside targeting functionality on the primary face of the  $\beta$ -CD, we  
435 started from the 6<sup>I</sup>-monoazido-6<sup>X</sup>-*N*-{3-[*N'*-(4'-nitro-3'-trifluoromethylphen-1'-  
436 yl)amino]propylamino}- $\beta$ -CD derivative **1** (Scheme 1). We have recently reported the synthesis of  
437 **1** as a mixture of regioisomers (Benkovics et al., 2017). Cyclodextrin derivative **1** already carries  
438 the desired NOPD moiety as well as an azido group that would allow the attachment of additional  
439 appendages through Huisgen [3+2] copper(I)-catalyzed azide-alkyne cycloadditions (CuAACs).  
440 Such reaction, which can be performed in water and is fully compatible with unprotected hydroxyl  
441 groups, requires the presence of terminal alkyne functions on the structures which is intended to be  
442 clicked to the macrocycle (Meldal & Tornøe, 2008). Indeed, the reaction of **1** with propargyl  $\alpha$ -D-  
443 mannose **3** using CuI as catalyst in a water-DMF mixture afforded **ManNOPD $\beta$ CD** as a light-  
444 sensitive yellow solid in 71% yield after column chromatography and dialysis purification. We  
445 observed that this reaction worked better when the catalyst was added as a water suspension on a  
446 pre-heated mixture in DMF of **1** and **3**. The structure of **ManNOPD $\beta$ CD** was first confirmed by  
447 ESI-TOF mass spectrometry, which showed only one peak of *m/z* corresponding to the expected  
448 [M+H]<sup>+</sup> ion. Both <sup>1</sup>H and <sup>13</sup>C NMR spectra were intricate due to the presence of several  
449 regioisomers in the product. However, it was possible to distinguish significant groups of signals  
450 which were not present in the starting azide **1** such as a singlet at  $\delta$  8.06 ppm in <sup>1</sup>H NMR, as well as  
451 two sets of signals at  $\delta$  143.5-143.4 and 127.3-126.5 ppm in <sup>13</sup>C NMR, that correspond to the 1,2,3-  
452 triazole residue that results from the cycloaddition. It should be noted that the resonances of the  
453 low-field signals corresponding to the 3-(trifluoromethyl)-4-nitrobenzenamine moiety were still  
454 evident in both <sup>1</sup>H and <sup>13</sup>C RMN. Taken together, all these data strongly suggested that conjugation  
455 of propargyl  $\alpha$ -D-mannose **3** had succeeded through the azide present in **1** without altering the rest  
456 of the structure of the latter.



457

458

Scheme 1

459

460

461

462

463

464

465

466

467

468

469

470

Next we extended this strategy to the attachment of an  $\alpha(1\rightarrow2)$ mannobioside residue on derivative **1**, as this disaccharide has been reported to be the key moiety of high mannose glycans that define the pathogenicity of a number of viruses and bacteria (Adams et al., 2004). In this regard, we prepared propargyl  $\alpha$ -D-mannopyranosyl-(1 $\rightarrow$ 2)- $\alpha$ -D-mannopyranoside starting from propargyl  $\alpha$ -D-mannose **3** (Scheme 1) according to the methodology recently described by Reina, Di Maio, Ramon-Soriano, Figueiredo & Rojo (2016) for the synthesis of similar  $\alpha(1\rightarrow2)$ mannobiosides. Thus, compound **3** was converted into the 3,4,6-tri-*O*-benzoyl derivative **7** in overall 33% yield after four successive steps: (i) benzylation of C-6 hydroxyl group (**4**) by treatment with BzCN at  $-40\text{ }^\circ\text{C}$  in the presence of catalytic amount of Et<sub>3</sub>N. These conditions, however, always led to a mixture of products including **4** and other over-benzyolated species that were conveniently isolated by chromatography column; (ii) selective acetylation of C-2 hydroxyl group (**5**) by reaction with trimethyl orthoacetate and camphorsulphonic acid (CSA), followed by


471 partial hydrolysis of the resulting intermolecular C-2,C-3 orthoester with 1 M aqueous HCl; (iii)  
472 benzylation of remaining C-3 and C-4 hydroxyl groups (**6**) by treatment with Bz<sub>2</sub>O, Et<sub>3</sub>N and 4-  
473 dimethylaminopyridine (4-DMAP); and (iv) deacetylation of C-2 hydroxyl group by using a 7%  
474 HCl solution in MeOH. Once prepared, compound **7** was used as acceptor for the mannoside donor  
475 **8** using TMSOTf as catalyst to yield **9** in 51% after purification, which was finally deprotected  
476 under Zemplén conditions giving the desired propargyl  $\alpha(1\rightarrow2)$ mannobioside **10** in 94%. Both ESI-  
477 TOF and NMR data confirmed the structure of **10**. Thus, anomeric protons for A and B mannose  
478 moieties gave two doublets at  $\delta$  5.27 and 5.02 ppm, respectively. Unequivocal assignation of these  
479 signals was carried out by selective 1D ROESY experiments (see supplementary data). In addition,  
480 propargylic proton was observed as a triplet at  $\delta$  2.91 ppm. Finally, compound **10** was conjugated  
481 with azide **1** under the same conditions described above to give **BiManNOPD $\beta$ CD** in 88% yield  
482 after chromatographic purification and dialysis. As in the case of **ManNOPD $\beta$ CD**,  
483 **BiManNOPD $\beta$ CD** was a mixture of regioisomers and showed complex NMR spectra, although a  
484 series of signals suggested that the conjugation had taken place including a singlet at  $\delta$  8.06 ppm in  
485 <sup>1</sup>H NMR, as well as two sets of signals at  $\delta$  144.1-144.0 and 127.7-126.0 ppm in <sup>13</sup>C NMR  
486 corresponding to the triazole linkage.

487 Finally, as model compounds to estimate the effect of the presence of the NOPD moiety we  
488 also prepared **Man $\beta$ CD** and **BiMan $\beta$ CD** by reaction of 6<sup>1</sup>-azido-6<sup>1</sup>-deoxy- $\beta$ -cyclodextrin **2** with  
489 propargyl derivatives **3** or **10** (Scheme 1) under the same conditions already indicated for the  
490 preparation of the NOPD-containing analogues. **Man $\beta$ CD** and **BiMan $\beta$ CD** were obtained in 92 and  
491 90% yield, respectively, after column chromatography. Since these compounds were  
492 regioisomerically pure their NMR spectra were much simpler. Indeed, apart from those signals  
493 indicating the formation of the 1,2,3-triazole spacer located around  $\delta$  8.10 ppm in <sup>1</sup>H NMR and  $\delta$   
494 143.4 and 123.8 ppm in <sup>13</sup>C NMR, it was possible to observe the anomeric protons of those  
495 mannose moieties directly linked to the spacer, as doublets at  $\delta$  5.02 and 5.21 ppm for **Man $\beta$ CD**  
496 and **BiMan $\beta$ CD**, respectively. These two signals allowed the unequivocal assignment of the rest of  
497 signals belonging to the mannose residues and the glucose appended with the linker through  
498 selective 1D TOCSY and 1D ROESY, as well as 2D HSQC, experiments (see supplementary data).  
499 MALDI-TOF-MS also confirmed the structure of these compounds as *m/z* peaks corresponded to  
500 the correct [M+Na]<sup>+</sup> ions for each one.

### 501 3.2. Supramolecular behavior

502 It is well known that the NOPD 3-(trifluoromethyl)-4-nitrobenzenamine moiety can be  
503 accommodated within the cavity of  $\beta$ -CD in aqueous solutions forming 1:1 complexes with an  
504 estimated binding constant (*K*) between  $200 \pm 16$  and  $300 \pm 50$  M<sup>-1</sup> (Taraszewska, Migut, &  
505 Koźbiał, 2003). This fact made us envisage that **ManNOPD $\beta$ CD** and **BiManNOPD $\beta$ CD**, both  
506 presenting simultaneously a chromophore moiety and a  $\beta$ -CD macrocycle, would probably undergo  
507 self-aggregation processes in water. This hypothesis was first tested by 2D ROESY NMR spectra in  
508 deuterated water (see Figure 1 and supplementary data). As can be seen, clear NOE cross-peaks  
509 were found between the three groups of low-field signals at  $\delta$  8.32-8.22, 8.16-8.11 and 6.97-6.90  
510 ppm belonging to the aromatic protons of the chromophore, and those multiplets appearing at  $\delta$   
511 4.29-3.16 ppm where H-3 and H-5 protons located at the inner wall of the CD cavity are  
512 overlapped. These results strongly suggested the inclusion of the NOPD inside the central hole of  
513 the macrocycle (Casas-Solvas et al., 2009). However, the complexity of the <sup>1</sup>H NMR spectra of  
514 these conjugates due to the presence of several regioisomers made difficult to propose any inclusion


515 geometry for the self-complexation. Although molecular modeling has indicated that the 3-  
516 (trifluoromethyl)-4-nitrobenzenamine moiety in the anti-androgen drug flutamide can enter the  $\beta$ -  
517 CD cavity through the secondary face protruding the NO<sub>2</sub> group through the primary rim  
518 (Taraszewska, Migut, & Koźbiał, 2003), to the best of our knowledge there is not any experimental  
519 evidence that support such spatial arrangement. Furthermore, ICD experiments suggested that more  
520 than one complex geometry might simultaneously occur during this interaction (Sortino et al.,  
521 2001). Consequently, at least three different self-inclusion modes could be proposed to explain the  
522 referred NOE cross-peaks in 2D ROESY NMR experiments measured for **ManNOPD $\beta$ CD** and  
523 **BiManNOPD $\beta$ CD** in water (Figure 2). Thus, the 3-(trifluoromethyl)-4-nitrobenzenamine moiety  
524 may undergo a monomeric intramolecular inclusion within the cavity through the primary face of  
525 the macrocycle if the trimethyldiamine linker was long and flexible enough to achieve this layout  
526 (structure A in Figure 2). In addition, one could envisage the formation of a head-to-head  
527 homodimer due to the interpenetration of the NOPD residues into the facing macrocycle cavities  
528 through their primary openings (structure B). The advantage of this spatial arrangement is the  
529 simultaneous cooperative participation of the two CD moieties, which might be crucial for the  
530 stability of the aggregation taking into account the low values on the binding constant estimated for  
531 the interaction of the 3-(trifluoromethyl)-4-nitrobenzenamine moiety with native  $\beta$ -CD. Finally, a  
532 linear supramolecular assembly involving  $n$  conjugate molecules could also be proposed  
533 considering the penetration of the NOPD residue of each molecule into the cavity of the following  
534 one through its secondary face in a head-to-tail fashion (structure C).



535

536 Figure 1. 2D-ROESY spectrum in D<sub>2</sub>O with WATERGATE (600 MHz, 25 °C, 200 ms of mixing  
537 time) for **BiManNOPD $\beta$ CD**. Cross-picks between the aromatic protons of the nitroaniline and the  
538 inner H-3 and H-5 protons of the  $\beta$ -CD are displayed in red.

539



540

541 Figure 2. Proposed structures for the supramolecular self-inclusion process of **ManNOPDβCD** in  
 542 water, which could be extended also for **BiManNOPDβCD**. A) Monomeric intramolecular self-  
 543 inclusion. B) Head-to-head dimeric interpenetration through the primary face of the macrocycle. C)  
 544 Head-to-tail polymeric self-aggregation through the secondary face of the macrocycle.

545 Assuming that each structure depicted in Figure 2 would lead to significantly different  
 546 hydrodynamic diameters ( $d_H$ ), we tried to gain insight into the self-aggregation structures of  
 547 **ManNOPDβCD** and **BiManNOPDβCD** by comparing their  $d_H$  values in  $D_2O$  with those for  $\beta$ -CD,  
 548 **ManβCD** and **BiManβCD** obtained by pulse-gradient stimulated echo (PGSE) NMR experiments  
 549 (Pregosin et al., 2005; Macchioni et al., 2008). Measured  $D$  values (Table 1) were used to estimate  
 550 the corresponding  $d_H$  of the diffusing species by using the Stokes-Einstein equation assuming a  
 551 spherical geometry for  $\beta$ -CD, **ManβCD** and **BiManβCD**, and a prolate spheroid shape for  
 552 **ManNOPDβCD** and **BiManNOPDβCD**. In addition, the  $D_2O$  viscosity value was assumed to be  
 553 constant, although it varies with the concentration of cyclodextrin derivatives, and equal to that  
 554 reported for  $H_2O$ . Thus, it is important to point out that such assumptions might render inaccurate  
 555 estimation of the hydrodynamic diameters, which should be, in turn, considered as apparent. The  $D$   
 556 value obtained for native  $\beta$ -CD was  $2.72 \times 10^{-10} \text{ m}^2 \text{ s}^{-1}$ , which involved a  $d_H$  of 1.78 nm. Such  $D$   
 557 value is in close agreement with those ( $2.64$ - $2.71 \times 10^{-10} \text{ m}^2 \text{ s}^{-1}$ ) previously reported for this  
 558 cicooligosaccharide when using the same technique (Guerrero-Martínez, González-Gaitano, Viñas,  
 559 & Tardajos, 2006; Cabaleiro-Lago, Nilsson, Valente, Bonini, & Söderman, 2006). Diffusion  
 560 coefficients for **ManβCD** and **BiManβCD** ( $2.64$  and  $2.36 \times 10^{-10} \text{ m}^2 \text{ s}^{-1}$ , respectively) decreased 3%  
 561 and 15%, respectively, as compared with  $\beta$ -CD, which indicated a slight increment of the molecular  
 562 size ( $d_H$  of 1.84 and 2.04 nm, respectively) consistent with the presence of an appended mannoside  
 563 or  $\alpha(1 \rightarrow 2)$ mannobioside moiety, respectively.

564 Table 1. Diffusion coefficients ( $D$ ) and hydrodynamic diameters ( $d_H$ ) values for  $\beta$ -CD, **Man $\beta$ CD**,  
 565 **BiMan $\beta$ CD**, **ManNOPD $\beta$ CD** and **BiManNOPD $\beta$ CD** (10 mM) obtained by PGSE NMR at 20 °C  
 566 in D<sub>2</sub>O

Compound	$D \times 10^{10} \text{ (m}^2 \text{ s}^{-1}\text{)}^a$	Sphere	Prolate spheroid	
		$d_H \text{ (nm)}^b$	Minor axes (nm) <sup>c</sup>	Major axes (nm) <sup>d</sup>
$\beta$ -CD	2.72	1.78		
<b>Man<math>\beta</math>CD</b>	2.64	1.84		
<b>BiMan<math>\beta</math>CD</b>	2.36	2.04		
<b>ManNOPD<math>\beta</math>CD</b>	2.20	2.20	1.84	3.14
<b>BiManNOPD<math>\beta</math>CD</b>	1.95	2.48	2.04	3.66

567 <sup>a</sup>The experimental error in the  $D$  values is  $\pm 2\%$ . <sup>b</sup>Obtained from the Stokes-Einstein equation  
 568 assuming a spherical geometry and the water viscosity  $\eta(\text{H}_2\text{O})$  to be constant and equal to  $0.890 \times$   
 569  $10^{-3} \text{ kg m}^{-1} \text{ s}^{-1}$  (www.knovel.com). <sup>c</sup>Fixed as the  $d_H$  of the **Man $\beta$ CD** and **BiMan $\beta$ CD** analogues.  
 570 <sup>d</sup>Calculated from the volume of the equivalent sphere.

571 In sharp contrast, the presence of the NOPD moiety on **ManNOPD $\beta$ CD** and  
 572 **BiManNOPD $\beta$ CD** analogues led to  $D$  values 24% and 39% smaller than that for  $\beta$ -CD, suggesting  
 573 that an aggregation process might take place. In a case like this, in which two conjugate molecules  
 574 are forming a supramolecular self-inclusion dimer, a prolate spheroid model of the same volume as  
 575 that for the equivalent sphere calculated from the Stokes-Einstein equation would be more adequate  
 576 to represent the actual shape of the aggregate. Considering that the NOPD moieties would be within  
 577 the  $\beta$ -CD cavities in such structure, we can assume that the minor axes of the spheroid representing  
 578 the self-associated head-to-head or head-to-tail structures of **ManNOPD $\beta$ CD** and  
 579 **BiManNOPD $\beta$ CD** equal the  $d_H$  values estimated for **Man $\beta$ CD** and **BiMan $\beta$ CD**. Interestingly, this  
 580 model depicted minimum major axis for the spheroids describing **ManNOPD $\beta$ CD** and  
 581 **BiManNOPD $\beta$ CD** of 3.14 and 3.66 nm, respectively, which turned out to be 1.71 and 1.79-fold  
 582 larger than  $d_H$  values for **Man $\beta$ CD** and **BiMan $\beta$ CD**. These results strongly suggested that  
 583 **ManNOPD $\beta$ CD** and **BiManNOPD $\beta$ CD** preferentially formed head-to-head homodimeric structure  
 584 B in water (Figure 2), although monomeric self-inclusion (structure A) and head-to-tail dimer C  
 585 containing only two molecules cannot be dismissed and might also occur to a lesser extent.

### 586 3.3. ConA binding affinity studies by ITC

587 The presence of mannose and  $\alpha(1 \rightarrow 2)$ mannobioside moieties on **ManNOPD $\beta$ CD** and  
 588 **BiManNOPD $\beta$ CD** endow these conjugates with targeting functionalities towards pathogens  
 589 showing mannose-receptor lectins on their surface. To test the biorecognition abilities of such  
 590 conjugates, we used concanavalin A (ConA) lectin from *Canavalia ensiformis* (Jack bean) as a  
 591 well-known model of mannose-specific lectins (Casas-Solvas et al., 2008). The non-containing-  
 592 NOPD analogues **Man $\beta$ CD** and **BiMan $\beta$ CD** were also used in this study for comparative purposes.  
 593 Binding studies were carried out by isothermal titration calorimetry (ITC), as this technique is well-  
 594 known to provide a full thermodynamic profile of the interaction. Indeed, the observed enthalpy  
 595 change of binding ( $\Delta H$ ) is directly measured from the thermogram, and both the binding constant  
 596 ( $K$ ) and the stoichiometry ( $n$ , which represents the [conjugate]:[ConA] ratio when the lectin binding  
 597 sites are fully saturated) are then estimated by using a nonlinear least square algorithm to fit the data  
 598 to a model of equal and independent binding sites, as this lectin has been reported to present a  
 599 single carbohydrate-binding site per monomer (Dam & Brewer, 2002).




600 Titration experiments were performed by injecting aliquots of solutions of each conjugates  
 601 into the calorimeter cell containing a solution of the lectin. Thermograms for each conjugate were  
 602 obtained by plotting heat released or absorbed after each injection against [conjugate]-[ConA]  
 603 molar ratio (see Figure 3 and supplementary data). Thermodynamic parameters for each interaction  
 604 are given in Table 2 and Figure 4.

605 Table 2. Thermodynamics and stability constants for the binding of conjugates **Man $\beta$ CD**,  
 606 **BiMan $\beta$ CD**, **ManNOPD $\beta$ CD** and **BiManNOPD $\beta$ CD** to ConA in 20 mM phosphate buffer (pH  
 607 7.2) containing 20 mM NaCl, 100  $\mu$ M CaCl<sub>2</sub> and 100  $\mu$ M MnCl<sub>2</sub> at 25 °C (*n* equal and independent  
 608 binding sites model).


Conjugate	<i>n</i> <sup>a</sup>	<i>K</i> (M <sup>-1</sup> )	$\Delta G^{\circ}$ (kcal mol <sup>-1</sup> )	$\Delta H$ (kcal mol <sup>-1</sup> )	$T\Delta S^{\circ}$ (kcal mol <sup>-1</sup> )
Me $\alpha$ -D-Man <sup>b</sup>	1.00	7600 $\pm$ 228	-5.29 $\pm$ 0.02	-6.80 $\pm$ 0.10	-1.51 $\pm$ 0.10
<b>Man<math>\beta</math>CD</b>	1.10 $\pm$ 0.02	9120 $\pm$ 356	-5.40 $\pm$ 0.02	-7.40 $\pm$ 0.13	-2.00 $\pm$ 0.13
<b>BiMan<math>\beta</math>CD</b>	1.10 $\pm$ 0.01	111000 $\pm$ 2200	-6.88 $\pm$ 0.01	-8.46 $\pm$ 0.03	-1.58 $\pm$ 0.03
<b>ManNOPD<math>\beta</math>CD</b>	1.25 $\pm$ 0.06	15700 $\pm$ 1130	-5.72 $\pm$ 0.04	-3.65 $\pm$ 0.20	2.07 $\pm$ 0.20
<b>BiManNOPD<math>\beta</math>CD</b>	1.07 $\pm$ 0.01	175000 $\pm$ 11400	-7.15 $\pm$ 0.04	-7.23 $\pm$ 0.08	-0.08 $\pm$ 0.09

609 <sup>a</sup>[conjugate]:[ConA] ratio when the lectin binding sites are fully saturated; <sup>b</sup>Chervenak & Toone,  
 610 1995.



611

612 Figure 3. Titration of ConA with **ManβCD** (top) and **ManNOPDβCD** (bottom) in 20 mM  
 613 phosphate buffer (pH 7.2) containing 20 mM NaCl, 100 μM CaCl<sub>2</sub> and 100 μM MnCl<sub>2</sub> at 25 °C.  
 614 The top panels show the raw calorimetric data indicating the amount of exchanged heat for each  
 615 injection of **ManβCD** or **ManNOPDβCD**. The area under each peak corresponds to the heat  
 616 amount released or absorbed upon binding of the mannosylated βCD to the lectin. As the titrations  
 617 progress the area under the peaks gradually becomes smaller because of the increasing saturation of  
 618 the sugar binding sites of the protein. Such area was integrated and plotted against the molar ratio of  
 619 the βCD derivative to ConA (as monomer). The smooth solid lines represent the best fit of the  
 620 experimental data to the model of *n* equal and independent binding sites.



621

622 Figure 4. Thermodynamic profiles including free energy ( $-\Delta G^0$ ), enthalpy ( $-\Delta H$ ), and entropy  
 623 changes ( $T\Delta S^0$ ) for the binding of conjugates **Man $\beta$ CD**, **BiMan $\beta$ CD**, **ManNOPD $\beta$ CD** and  
 624 **BiManNOPD $\beta$ CD** to ConA in 20 mM phosphate buffer (pH 7.2) containing 20 mM NaCl, 100  $\mu$ M  
 625 CaCl<sub>2</sub> and 100  $\mu$ M MnCl<sub>2</sub> at 25 °C.

626 As can be seen, the interaction of conjugates **Man $\beta$ CD** and **BiMan $\beta$ CD** lacking NOPD  
 627 moieties is clearly exothermic. The corresponding thermograms present a set of negative peaks  
 628 indicating a heat release after each injection which becomes smaller as the titration successes.  
 629 Thermodynamic profiles are enthalpy-driven in both cases, with large negative (i.e. favorable)  
 630 enthalpic contributions partially compensated by smaller negative (i.e. unfavorable) entropic terms.  
 631 This behavior has been reported as typical energetics of protein–carbohydrate associations (Casas-  
 632 Solvas et al., 2008). Indeed, thermodynamic data for the interaction of methyl  $\alpha$ -D-mannoside (Me  
 633  $\alpha$ -D-Man) with ConA (Chervenak & Toone, 1995) are given for comparison (Table 2 and Figure 4).  
 634 In fact,  $K$  values for Me  $\alpha$ -D-Man and **Man $\beta$ CD** (7600 and 9120 M<sup>-1</sup>, respectively) are very similar,  
 635 indicating that the presence of the triazole linker and the  $\beta$ -CD macrocycle at the anomeric position  
 636 of the sugar do not have any significant effect on the association with the lectin. In the case of  
 637 **BiMan $\beta$ CD**, however, the binding constant (111000 M<sup>-1</sup>) turned out to be 12-fold stronger than that  
 638 for **Man $\beta$ CD**, which implies that  $\alpha(1\rightarrow2)$ mannobioside residue is a far better ligand for ConA  
 639 lectin than the mannose monosaccharide. Such increased avidity arises from a 14% more favorable  
 640 enthalpic contribution along with a 21% less unfavorable entropic factor, which may be reasoned in  
 641 terms of a better fit of the  $\alpha(1\rightarrow2)$ mannobioside moiety within the carbohydrate-binding site of the  
 642 protein.

643 Interestingly, the presence of the NOPD appendage on **ManNOPD $\beta$ CD** and  
 644 **BiManNOPD $\beta$ CD** sharply modifies the thermodynamic profiles of association to ConA leading to  
 645 a much more complex behavior (see Figure 3 and supplementary data). Thus, although negative  
 646 exothermic peaks initially appeared, they quickly became positive (i. e. endothermic) after a few  
 647 injections until reached a plateau and began to decrease gradually. This behavior was especially  
 648 evident for **ManNOPD $\beta$ CD**, although it also succeeded in the case of **BiManNOPD $\beta$ CD**. These  
 649 data suggested that two different processes seemed to occur simultaneously. Indeed, dilution  
 650 processes for these two conjugates were clearly endothermic showing intensity that decreased along  
 651 the experiment while their analogues **Man $\beta$ CD** and **BiMan $\beta$ CD** not presenting NOPD moieties  
 652 gave negligible dilution peaks. Such results might be due to the disassembly of self-aggregates

653 during dilution (Casas-Solvas et al., 2009), although depletion was linear and thus could not be  
654 fitted to any dissociation model. In any case, it is clear that this endothermic dilution feature  
655 compensates the exothermic binding event of the sugar appendage to the lectin. Initially, the latter  
656 process is more energetic and dominates the thermogram, given neat negative peaks. However, as  
657 the experiment progresses, binding becomes less intense probably due to the increasing saturation  
658 of the sugar binding sites of the protein and endothermic dilution gradually takes control on the  
659 resulting peaks. As a result, thermodynamic parameters obtained for **ManNOPD $\beta$ CD** and  
660 **BiManNOPD $\beta$ CD** would contain information about both events and thus should be considered as  
661 apparent.


662 As can be seen from Table 2 and Figure 4, thermodynamic profiles for the interaction of  
663 **ManNOPD $\beta$ CD** and **BiManNOPD $\beta$ CD** steeply differ from those previously discussed for  
664 **Man $\beta$ CD** and **BiMan $\beta$ CD**. Although both are still enthalpy-driven, in the case of **ManNOPD $\beta$ CD**  
665 enthalpic term also contributes favorably in 36% to the binding, suggesting that a more efficient  
666 dehydration might take place. In consequence, despite the fact that this conjugate shows a  $\Delta H$  value  
667 49% smaller than that for its **Man $\beta$ CD** analogue, the binding constant turned out to be 1.7-fold  
668 stronger. It is difficult to unequivocally explain this behavior, but it might be due to a multivalent  
669 effect of the carbohydrate caused by the homodimerization process suggested by NMR and DLS  
670 data. However, it should not be discounted that the aromatic moiety may somehow take part in the  
671 binding process with the protein, since it is well known that many lectins possess hydrophobic  
672 binding sites, in particular around the site where aglycon groups would localize upon carbohydrate–  
673 lectin complexation (Casas-Solvas et al., 2008). Similarly, **BiManNOPD $\beta$ CD** gave a  $K$  value 1.6-  
674 fold larger than that found for the conjugate **BiMan $\beta$ CD**, although in this case the entropic term  
675 was almost negligibly unfavorable and contributed less than 1% to the free energy change of the  
676 binding. As can be seen from the thermograms (see Figure 3 and supplementary data), the  
677 endothermic dilution process is less intense for **BiManNOPD $\beta$ CD** as compared to  
678 **ManNOPD $\beta$ CD**, and thus seems not to be enough to fully compensate the negative entropy change  
679 that arises from the simple interaction of the carbohydrate moiety observed for **BiMan $\beta$ CD**. In any  
680 case, it is clear that the presence of NOPD residue on both **ManNOPD $\beta$ CD** and **BiManNOPD $\beta$ CD**  
681 clearly increases the avidity of ConA for these conjugates.

#### 682 3.4. Spectroscopic and photochemical behavior

683 The absorption spectra of **ManNOPD $\beta$ CD** and **BiManNOPD $\beta$ CD** together with that of N-(3-  
684 aminopropyl)-3-(trifluoromethyl)-4-nitrobenzenamine chosen as suitable model compound are  
685 shown in Figure 5. As expected, the spectral profiles of the CD derivatives are dominated by the  
686 dominant absorption of the nitroaniline moiety (Caruso, Petralia, Conoci, Giuffrida, & Sortino,  
687 2007). However, a small but indicative blue shift of the absorption maxima (ca. 7 nm) for both  
688 **ManNOPD $\beta$ CD** and **BiManNOPD $\beta$ CD** with respect to the model compound is observed (see  
689 later). Such a shift is in line with the supramolecular behavior and can be due to lower polarity of  
690 the CD cavity experienced by the nitroaniline chromophore upon formation of the inclusion  
691 complexes. In fact, due to the large difference of the dipole moments between the ground and first  
692  $\pi, \pi^*$  state responsible for the first large absorption band (Sortino et al. 2001), one would expect a  
693 blue shift of this band going from water to a less polar solvent.

694


695



697

698 Figure 5. Normalized absorption spectra in aqueous solution of **ManNOPDβCD** (dashed),  
 699 **BiManNOPDβCD** (dashed-dotted) and N-(3-aminopropyl)-3-(trifluoromethyl)-4-nitrobenzenamine  
 700 (solid)

701 The NO delivery capability of the CD derivatives under light stimuli was investigated using an  
 702 ultrasensitive NO electrode for the direct and real-time monitoring of this transient species. Such  
 703 electrode directly reveals NO with high sensitivity (nM concentrations) by an amperometric  
 704 technique (Coneski and Schoenfisch, 2012). Optically matched aqueous solutions of  
 705 **ManNOPDβCD** and **BiManNOPDβCD** and, for comparison, the model compound, were  
 706 subjected to alternate cycles of light ( $\lambda_{exc} = 405$  nm) and dark. The results illustrated in Figure 6  
 707 provide unambiguous evidence that both **ManNOPDβCD** and **BiManNOPDβCD** are very stable in  
 708 the dark and supply NO exclusively under irradiation with visible light. Note that, the rate of  
 709 photorelease is very similar for both the CD derivatives and higher than that observed for the model  
 710 compound. This increased NO photodelivery efficiency is not surprising and can be due to an active  
 711 role of the CD cavity which act as a nanoreactor that provides a low polarity environment and  
 712 abstractable hydrogens nearby the phenoxy radical intermediate involved in the NO photorelease  
 713 mechanism (see Caruso, Petralia, Conoci, Giuffrida, & Sortino, 2007). A similar behavior has been  
 714 already observed for this NOPD encapsulated in micelles of Pluronic (Taladriz-Blanco, 2014) and  
 715 amphiphilic calixarenes (Di Bari, 2016).



716  
 717 Figure 6. NO release profile observed for 80  $\mu\text{M}$  aqueous solutions of **ManNOPD $\beta$ CD** (*a*) and  
 718 **BiManNOPD $\beta$ CD** (*b*) and an optically matched aqueous solution of the model compound N-(3-  
 719 aminopropyl)-3-(trifluoromethyl)-4-nitrobenzenamine (*c*).  $\lambda_{\text{exc}} = 405 \text{ nm}$

720

#### 721 4. Conclusions

722 In summary, we have synthesized two new  $\beta$ -CD derivatives containing on their primary  
 723 face two randomly appended functional moieties: a) a NO photodonor 4-nitro-3-  
 724 (trifluoromethyl)aniline group, and b) a mannose or  $\alpha(1\rightarrow2)$ mannobioside residue as targeting  
 725 functionalities to provide the conjugates with avidity for mannose-binding lectins. Both bifunctional  
 726 cyclooligomers were found to be fully soluble in water. As initially hypothesized, the conjugates  
 727 underwent supramolecular self-aggregation processes due to the self-inclusion of the NOPD moiety  
 728 within the  $\beta$ -CD cavity. In particular, 2D ROESY and PGSE NMR experiments suggested that they  
 729 formed supramolecular head-to-head homodimers that might occur by the interpenetration of the  
 730 nitroaniline residues into the facing macrocycle cavities through their primary openings. The bio-  
 731 recognition abilities of the conjugates were tested towards concanavalin A lectin by isothermal  
 732 titration calorimetry. Thermograms were complex since at least two different thermodynamic  
 733 processes took place: an exothermic lectin binding event and an endothermic process during the  
 734 dilution of the conjugates that might be reasoned in terms of aggregates disassembly. It was found  
 735 that  $\alpha(1\rightarrow2)$ mannobioside moiety provided lectin binding constants two orders of magnitude larger  
 736 than that for mannose residue. In addition, the presence of nitroaniline enhanced the binding  
 737 interaction with ConA between 1.6 and 1.7 times with respect to the non-containing-nitroaniline  
 738 analogue structures. This effect might be due to the multivalent effect of the carbohydrate caused by  
 739 homodimerization. Despite the formation of supramolecular structures both CD derivatives are able  
 740 to release NO under the control of visible light with efficiency even higher than that of the

741 unfunctionalized NOPD unit. In this regard, the CD cavity as a nanoreactor with reduced polarity  
742 and presence of easily abstractable H-atom, indispensable in the mechanism of the NO  
743 photorelease, is envisaged to play a key role.

744

## 745 **Acknowledgements**

746 The authors acknowledge the Spanish Ministry of Economy and Competitiveness (Grants  
747 CTQ2013-48380-R and CTQ2017-900-50R) and the European Union through FP7-PEOPLE-2013-  
748 ITN (<http://itn-cyclonhit.eu>) project (Grant Agreement no. 608407)

749

## 750 **Appendix A. Supplementary data**

751 Supplementary data associated with this article can be found, in the online version, at (to be  
752 completed when accepted)

753

## 754 **References**

755 Adams, E. W., Ratner, D. M., Bokesch, H. R., McMahon, J. B., O'Keefe, B. R., & Seeberger, P. H.  
756 (2004). Oligosaccharide and glycoprotein microarrays as tools in HIV glycochemistry: glycan-  
757 dependent gp120/protein interactions, *Chemistry & Biology*, 2004, 11(6), 875-881.  
758 <http://dx.doi.org/10.1016/j.chembiol.2004.04.010>

759 Bausanne, I., Benito, J. M., Ortiz Mellet, C., García Fernandez, J. M., Law, H., & Defaye, J.,  
760 (2000). Synthesis and comparative lectin-binding affinity of mannosyl-coated  $\beta$ -cyclodextrin-  
761 dendrimer constructs, *Chemical Communication*, 2000(16), 1489-1490.  
762 <http://dx.doi.org/10.1039/b003765f>

763 Benito, J. M., Gomez-García, M., Ortiz Mellet, C., Bausanne, I., Defaye, J., & García Fernandez, J.  
764 M. (2004). Optimizing saccharide-directed molecular delivery to biological receptors: design,  
765 synthesis, and biological evaluation of glycodendrimer–cyclodextrin conjugates. *Journal of the*  
766 *American Chemical Society*, 126(33), 10355-10363. <http://dx.doi.org/10.1021/ja047864v>

767 Benkovics, G., Perez-Lloret, M., Afonso, D., Darcsi, A., Béni, S., Fenyvesi, E., et al. (2017). A  
768 multifunctional  $\beta$ -cyclodextrin conjugate photodelivering nitric oxide with fluorescence reporting.  
769 *International Journal of Pharmaceutics*, 531(2), 614-620.  
770 <https://dx.doi.org/10.1016/j.ijpharm.2017.05.023>

771 Cabaleiro-Lago, C., Nilsson, M., Valente, A. J. M., Bonini, M., & Söderman, O. (2006). NMR  
772 diffusometry and conductometry study of the host–guest association between  $\beta$ -cyclodextrin and  
773 dodecane 1,12-bis(trimethylammonium bromide). *Journal of Colloid and Interface Science*, 300(2),  
774 782-787. <http://dx.doi.org/10.1016/j.jcis.2006.04.016>

775 Carpenter, A. W., & Schoenfisch, M. H. (2012). Nitric oxide release: Part II. Therapeutic  
776 applications, *Chemical Society Reviews*, 41(10), 3742-3752. <http://dx.doi.org/10.1039/c2cs15273h>

- 777 Caruso, E. B., Petralia, S., Conoci, S., Giuffrida, S., & Sortino, S. (2007). Photodelivery of nitric  
778 oxide from water-soluble platinum nanoparticles. *Journal of the American Chemical Society*,  
779 *129*(3), 480-481. <http://dx.doi.org/10.1021/ja067568d>
- 780 Casas-Solvas, J. M., Ortiz-Salmerón, E., García-Fuentes, L., & Vargas-Berenguel, A. (2008)  
781 Ferrocene–mannose conjugates as electrochemical molecular sensors for concanavalin A lectin.  
782 *Organic and Biomolecular Chemistry*, *6*(22), 4230-4235. <http://dx.doi.org/10.1039/b809542f>
- 783 Casas-Solvas, J. M., Ortiz-Salmerón, E., Fernández, I., García-Fuentes, L., Santoyo-González, F.,  
784 Vargas-Berenguel, A. (2009). Ferrocene– $\beta$ -cyclodextrin conjugates: synthesis, supramolecular  
785 behavior, and use as electrochemical sensors. *Chemistry – A European Journal*, *15*(33), 8146-8162.  
786 <http://dx.doi.org/10.1002/chem.200900593>
- 787 Casas-Solvas, J. M., & Vargas-Berenguel, A. (2016). Glycoclusters and their applications as anti-  
788 infective agents, vaccines, and targeted drug delivery systems. In K. J. Stine (Ed.), *Carbohydrate*  
789 *Nanotechnology* (Chapter 7, pp. 175-210). Hoboken: John Wiley & Sons, Inc.  
790 <http://dx.doi.org/10.1002/9781118860212.ch7>
- 791 Chervenak, M. C., & Toone, E. J. (1995). Calorimetric analysis of the binding of lectins with  
792 overlapping carbohydrate-binding ligand specificities. *Biochemistry*, *34*(16), 5685-5695.  
793 <http://dx.doi.org/10.1021/bi00016a045>
- 794 Cohen, M. L., (2000). Changing patterns of infectious disease, *Nature*, *406*(6797), 762-767.  
795 <http://dx.doi.org/10.1038/35021206>
- 796 Coneski, P. N., & Schoenfish, M. H. (2012). Nitric oxide release: Part III. Measurement and  
797 reporting. *Chemical Society Reviews*, *41*(10), 3753-3758. <http://dx.doi.org/10.1039/c2cs15271a>
- 798 Conoci, S., Petralia, S., & Sortino, S. (2006). Use of nitroaniline derivatives for the production of  
799 nitric oxide. Patent US 8766006 B2
- 800 Cutrone, G., Casas-Solvas, J. M., & Vargas-Berenguel, A. (2017). Cyclodextrin-Modified inorganic  
801 materials for the construction of nanocarriers, *International Journal of Pharmaceutics*, *531*(2), 621-  
802 639. <http://dx.doi.org/10.1016/j.ijpharm.2017.06.080>
- 803 Dam, T. K., & Brewer, F. (2002). Thermodynamic studies of lectin–carbohydrate interactions by  
804 isothermal titration calorimetry. *Chemical Reviews*, *102*(2), 387-430. <http://dx.doi.org/10.1021/cr000401x>
- 806 Di Bari, I., Picciotto, R., Granata, G., Blanco, A. R., Consoli, G. M. L., & Sortino, S. (2016). A  
807 bactericidal calix[4]arene-based nanoconstruct with amplified NO photorelease, *Organic &*  
808 *Biomolecular Chemistry*, *14*(34), 8047-8052. <http://dx.doi.org/10.1039/c6ob01305h>
- 809 Duchêne, D., & Bochot, A. (2016). Thirty years with cyclodextrins. *International Journal of*  
810 *Pharmaceutics*, *514*(1), 58-72. <http://dx.doi.org/10.1016/j.ijpharm.2016.07.030>
- 811 Erdmann, R. S., & Wennemans, H. (2010). Functionalizable collagen model peptides. *Journal of*  
812 *the American Chemical Society*, *132*(40), 13957-13959. <http://dx.doi.org/10.1021/ja103392t>
- 813 Figdor, C. G., van Kooyk, Y., & Adema, G. J. (2002). C-type lectin receptors on dendritic cells and  
814 langerhans cells, *Nature Reviews Immunology*, *2*(2), 77–84. <http://dx.doi.org/10.1038/nri723>



- 815 Fraix, A., Marino, N., & Sortino, S. (2016). Phototherapeutic release of nitric oxide with engineered  
816 nanoconstructs. In S. Sortino (Ed.), *Light-Responsive Nanostructured Systems for Applications in*  
817 *Nanomedicine*, Topics in Current Chemistry, 370 (pp. 225-257). Heidelberg: Springer International  
818 Publishing Switzerland. [http://dx.doi.org/10.1007/978-3-319-22942-3\\_8](http://dx.doi.org/10.1007/978-3-319-22942-3_8)
- 819 Gade, M., Khandelwal, P., Sangabathuni, S., Bavireddi, H., Murthy, R. V., Poddar, P., et al. (2016).  
820 Immobilization of multivalent glycoprobes on gold surfaces for sensing proteins and macrophages.  
821 *Analyst*, 141(7), 2250-2258. <http://dx.doi.org/10.1039/c5an02336j>
- 822 Guerrero-Martínez, A., González-Gaitano, G., Viñas, M. H., & Tardajos, G (2006). Inclusion  
823 complexes between  $\beta$ -cyclodextrin and a gemini surfactant in aqueous solution: an NMR study.  
824 *Journal of the Physical Chemistry B*, 110(28), 13819-13828. <http://dx.doi.org/10.1021/jp0615813>
- 825 Halpenny, G. M., & Mascharak, P. K. (2010). Emerging antimicrobial applications of nitric oxide  
826 (NO) and NO-releasing materials, *Anti-Infective Agents in Medicinal Chemistry*, 9(4), 187-197.  
827 <http://dx.doi.org/10.2174/187152110794785086>
- 828 Hartmann, M., Betz, P., Sun, Y., Gorb, S. N., Lindhorst, T. K., & Krueger, A. (2012). Saccharide-  
829 modified nanodiamond conjugates for the efficient detection and removal of pathogenic bacteria.  
830 *Chemistry – A European Journal*, 18(21), 6485-6492. <http://dx.doi.org/10.1002/chem.201104069>
- 831 Laxminarayan, R., Duse, A., Watal, C., Zaidi, A. K. , Wertheim, H. F., Sumpradit, N., et al.(2013).  
832 Antibiotic resistance-the need for global solutions, *The Lancet Infectious Diseases Commission*,  
833 13(12), 1057-1098. [http://dx.doi.org/10.1016/S1473-3099\(13\)70318-9](http://dx.doi.org/10.1016/S1473-3099(13)70318-9)
- 834 Macchioni, A., Ciancaleoni, G., Zuccaccia, C., & Zuccaccia, D. (2008). Determining accurate  
835 molecular sizes in solution through NMR diffusion spectroscopy. *Chemical Society Reviews*, 37(3),  
836 479-489. <http://dx.doi.org/10.1039/b615067p>
- 837 Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmelic, Y., Falagas, M. E., Giske, C. G., et  
838 al. (2012). Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an  
839 international expert proposal for interim standard definitions for acquired resistance. *Clinical*  
840 *Microbiology and Infection*, 18(3), 268-281. <http://dx.doi.org/10.1111/j.1469-0691.2011.03570.x>
- 841 Mazzaglia, A., Sciortino, M. T., Kandoth, N., & Sortino, S. (2012). Cyclodextrin-based  
842 nanoconstructs for photoactivated therapies. *Journal of Drug Delivery Science and Technology*,  
843 22(3), 235-242. [http://dx.doi.org/10.1016/s1773-2247\(12\)50034-1](http://dx.doi.org/10.1016/s1773-2247(12)50034-1)
- 844 Meldal, M., & Tornøe, C. W. (2008). Cu-catalyzed azide-alkyne cycloaddition. *Chemical Reviews*,  
845 108(8), 2952–3015. <http://dx.doi.org/10.1021/cr0783479>.
- 846 Perrin, D. D., & Armarego, W. F. L. (1989). *Purification of Laboratory Chemicals*. (3rd ed.).  
847 Oxford: Pergamon.
- 848 Poláková, M., Beláňová, M., Mikušová, K., Lattová, E., & Perreault, H. (2011). Synthesis of 1,2,3-  
849 triazolo-linked octyl (1→6)- $\alpha$ -D-oligomannosides and their evaluation in mycobacterial  
850 mannosyltransferase assay. *Bioconjugate Chemistry*, 22(2), 289-298.  
851 <http://dx.doi.org/10.1021/bc100421g>

- 852 Popielec, A., & Loftsson, T. (2017). Effects of cyclodextrins on the chemical stability of drugs.  
853 *International Journal of Pharmaceutics*, 531(2), 532-542.  
854 <http://dx.doi.org/10.1016/j.ijpharm.2017.06.009>
- 855 Pregosin, P. S., Kumar, P. G. A., & Fernandez, I. (2005). Pulsed Gradient Spin-Echo (PGSE)  
856 Diffusion and  $^1\text{H}$ ,  $^{19}\text{F}$  Heteronuclear Overhauser Spectroscopy (HOESY) NMR Methods in  
857 Inorganic and Organometallic Chemistry: Something Old and Something New. *Chemical Reviews*,  
858 105(8), 2977-2998. <http://dx.doi.org/10.1021/cr0406716>
- 859 Reina, J. J., Di Maio, A., Ramos-Soriano, J., Figueiredo, R. C., & Rojo, J. (2016). Rapid and  
860 efficient synthesis of  $\alpha(1-2)$ mannobiosides. *Organic & Biomolecular Chemistry*, 14(10), 2873-  
861 2882. <http://dx.doi.org/10.1039/c6ob00083e>
- 862 Riccio, D. A., & Schoenfish, M. H. (2012). Nitric oxide release: part I. Macromolecular scaffolds.  
863 *Chemical Society Review*, 41(10), 3731-3741. <http://dx.doi.org/10.1039/c2cs15272j>
- 864 Schuster, J, Vijayakrishnan, B., & Davis, B. G. (2015). Chain-growth polyglycosylation: synthesis  
865 of linker equipped mannosyl oligomers. *Carbohydrate Research*, 403(11), 135-141.  
866 <http://dx.doi.org/10.1016/j.carres.2014.06.021>
- 867 Seabra, A. B., & Durán, N. (2010). Nitric oxide-releasing vehicles for biomedical applications.  
868 *Journal of Materials Chemistry*, 20(9), 1624-1637. <http://dx.doi.org/10.1039/b912493b>
- 869 Sortino, S., Giuffrida, S, De Guidi, G., Chillemi, R., Petralia, S., Marconi, G, et al. (2001). The  
870 photochemistry of flutamide and its inclusion complex with  $\beta$ -cyclodextrin. Dramatic effect of the  
871 microenvironment on the nature and on the efficiency of the photodegradation pathways.  
872 *Photochemistry and Photobiology*, 73(1), 6-13. [http://dx.doi.org/10.1562/0031-](http://dx.doi.org/10.1562/0031-8655(2001)0730006tpofai2.0.co2)  
873 [8655\(2001\)0730006tpofai2.0.co2](http://dx.doi.org/10.1562/0031-8655(2001)0730006tpofai2.0.co2)
- 874 Sortino, S., Marconi, G., & Condorelli G. (2001). New insight on the photoreactivity of the  
875 phototoxic anti-cancer flutamide: photochemical pathways selectively locked and unlocked by  
876 structural changes upon drug compartmentalization in phospholipid bilayer vesicles. *Chemical*  
877 *Communication*, 2001(13), 1226-1227. <http://dx.doi.org/10.1039/b102359b>
- 878 Szakács, G., Paterson, J. K. , Ludwig, J. A., Booth-Gent, C., & Gottesman, M. M. (2006). Targeting  
879 multidrug resistance in cancer. *Nature Reviews Drug Discovery*, 5(3), 219-234.  
880 <http://dx.doi.org/10.1038/nrd1984>
- 881 Taladriz-Blanco P., & de Oliveira, M. G. (2014). Enhanced photochemical nitric oxide release  
882 from a flutamidederivative incorporated in Pluronic F127 micelles. *Journal of Photochemistry*  
883 *and Photobiology A: Chemistry*, 293, 65-71.  
884 <http://dx.doi.org/10.1016/j.jphotochem.2014.07.022>  
885
- 886 Taraszewska, J., Migut, K., & Koźbiał, M. (2003). Complexation of flutamide by native and  
887 modified cyclodextrins. *Journal of Physical Organic Chemistry*, 16(2), 121-126.  
888 <http://dx.doi.org/10.1002/poc.582>
- 889 Taubes, G. (2008). The bacteria fight back. *Science*, 321(5887), 356-361.  
890 <http://dx.doi.org/10.1126/science.321.5887.356>

- 891 van der Peet, P., Gannon, C. T., Walker, I., Dinev, Z., Angelin, M., Tam, S., et al. (2006). Use of  
892 click chemistry to define the substrate specificity of *Leishmania*  $\beta$ -1,2-mannosyltransferases.  
893 *ChemBioChem*, 7(9), 1384-1391. [http://dx.doi.org/ 10.1002/cbic.200600159](http://dx.doi.org/10.1002/cbic.200600159)
- 894 Vargas-Berenguel, A., Ortega-Caballero, F., & Casas-Solvas, J. M. (2007). Supramolecular  
895 chemistry of carbohydrate clusters with cores having guest binding abilities. Mini-Reviews in  
896 *Organic Chemistry*, 4(1), 1-14. <http://dx.doi.org/10.2174/157019307779815901>
- 897 Wang, P. G., Cai, T. B., & Taniguchi, N. (Eds.) (2005). *Nitric Oxide Donors for Pharmaceutical*  
898 *and Biological Applications*. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA.  
899 <http://dx.doi.org/10.1002/3527603751>
- 900 Wang, P. G., Xian, M., Tang, X., Wu, X., Wen, Z., Cai, T., et al. (2002). Nitric oxide donors:  
901 chemical activities and biological applications. *Chemical Reviews*, 102(4), 1091-1134.  
902 <http://dx.doi.org/10.1021/cr0000401>
- 903 Woodford, N., (2005). Novel agents for the treatment of resistant Gram-positive infections. *Expert*  
904 *Opinion on Investigational Drugs*, 12(2), 117-137. <http://dx.doi.org/10.1517/13543784.12.2.117>
- 905 Zhao, J., Liu, Y., Park, H.-J., Boggs, J. M., & Basu, A. (2012). Carbohydrate-coated fluorescent  
906 silica nanoparticles as probes for the galactose/3-sulfogalactose carbohydrate-carbohydrate  
907 interaction using model systems and cellular binding studies. *Bioconjugate Chemistry*, 23(6), 1166-  
908 1173. <http://dx.doi.org/10.1021/bc2006169>